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Abstract 
Background 
Multiple Sclerosis (MS) is a chronic neurological disease, which poses 
significant psychological challenges. The purpose of this systematic review 
was to identify factors that are associated with anxiety in people with MS 
(PwMS). It aimed to examine the strength of evidence for factors associated 
with anxiety symptoms and identify limitations of existing studies.  
 
Method and Results 
One hundred and thirty one studies met inclusion criteria and were included in 
the review. A narrative synthesis was then conducted. Anxiety was found to 
be associated with a variety of demographic, physical, psychological, 
cognitive and social factors. A consistent finding was that anxiety was strongly 
associated with both high level of disability and low quality of life. A strong 
association between anxiety and depression was also found. 
 
Conclusion 
Implications for these results are discussed and a preliminary model of 
understanding anxiety in the context of MS is outlined. Given the overlap 
between anxiety and depression a transdiagnostic treatment approach is 
suggested. In light of the shortcomings of extant studies, suggestions for 
future research are offered. 
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1. INTRODUCTION 
Multiple Sclerosis (MS) is a chronic inflammatory neurological condition of the 
central nervous system(DeLuca, Genova, Hillary, & Wylie, 2008). The illness 
occurs when the protective myelin sheath of nerve fibers in the brain and 
spinal cord become damaged, disrupting the transfer of messages from the 
brain to other parts of the body (National MS Society, 2012). There are 
various types of disease courses including: a benign course, a relapsing-
remitting course (RR), which often progresses into a secondary progressive 
course (SP); and a type that is progressive from its onset (PP)(NHS Choices, 
2013). Due to the unpredictability of the course of the illness, and the lack of 
treatments available, the main goals of intervention are usually to delay 
progression, relieve symptoms and treat any mental health issues that arise 
(Burks, Bigley, & Hill, 2009). Mental health problems, such as depression and 
anxiety, have been found to be particularly common among people with 
Multiple Sclerosis (PwMS) (Janssens et al, 2003) and to date most of the 
literature has focused on depression in PwMS. This study therefore aims to 
broaden current knowledge by focusing exclusively on the role of anxiety in 
PwMS. 
 
Anxiety can be defined as an excessive feeling of unease and worry which 
individuals find difficult to control, and consequently interferes with everyday 
functioning (American Psychiatric Association, 2000). For PwMS, anxiety may 
be severe and prolonged due to the individual’s concern about the uncertain 
outcome of future episodes and the potential seriousness of the symptoms 
(Cecile et al., 2004). Worldwide estimates of the proportion of the population 
who are likely to suffer from anxiety in their lifetime range between 0.8% and 
6.4%(Kessler & Wang, 2008). However, for PwMS, anxiety has been found to 
affect between 15.8% and 57% of the population (Feinstein et al, 1999; 
Garfield et al, 2012). Anxiety is amongst the most important factors to 
investigate for PwMS as, if untreated, it can significantly impact quality of life, 
treatment adherence and symptoms(Mohr & Cox, 2001). Therefore, it is 
widely agreed that identification of symptoms and treatment should be 
introduced at the earliest opportunity (Dahl et al, 2009). However, current 
knowledge of anxiety and its treatment in PwMS is limited by the lack of 
research on why PwMS experience anxiety. 
 
The purpose of the current review is to systematically identify existing 
literature that focused on anxiety among PwMS. The aims are a) to gain an 
overview of the strength of evidence for factors associated with anxiety in the 
context of MS b) to identify methodological problems, gaps within the 
literature and directions for future research. A reliable overview of the field of 
research is likely to help clinicians improve the wellbeing of PwMS and to gain 
a greater understanding of factors that are linked to anxiety so that these 
could be targeted within interventions.  
2. METHOD 
2. 1. Search Strategy and Selection Criteria 
 
The systematic review protocol and data extraction forms were designed in 
accordance with the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA)(Moher, Liberati, Tetzlaff, Altman, & Group, 2009). 
Electronic databases (MEDLINE, EMBASE, Web of Science, BIOSIS, KCI, 
SciELO, CINAHL and Psychinfo) were searched for studies between January 
1980 and September 2016 (see Appendix A for search terms). The screening 
process then took place which involved: removing duplicates; title screening; 
excluding irrelevant titles; abstract screening; then full-text assessment 
against eligibility criteria.  
2. 2. Inclusion and Exclusion Criteria  
 
Cross-sectional and prospective studies were included that were published 
empirical quantitative research reports examining anxiety in PwMS. 
Intervention studies were not included in this review as data collected in 
randomised trials may not be applicable to the wider population of patients 
because trials use such rigorous inclusion criteria to get an artificially 
homogenous group of patients (Rothwell, 2005). The review included all 
available studies that identified clinically relevant anxiety, i.e. anxiety severe 
enough to warrant clinical intervention that was measured by clinical judgment 
or a validated, appropriate multi-item measure. Single item measures were 
excluded due to their vulnerability to random measurement errors and lack of 
internal consistency reliability (Hoeppner, Kelly, Urbanoski, & Slaymaker, 
2011). The factors associated with anxiety were examined. Prevalence 
estimates were also obtained for Generalised Anxiety Disorder (GAD), 
Obsessive Compulsive Disorder (OCD), Post-traumatic Stress Disorder 
(PTSD) and Social Anxiety. Ambiguities as to whether a study met the 
inclusion criteria were resolved through discussion between the authors (EB 
and TC).  
2. 3. Data Extraction 
 
Study titles were screened first, followed by abstracts by a research assistant 
in collaboration with the primary researcher (EB). The full texts were then 
screened by EB and all ineligible papers were excluded. Information for each 
eligible study was extracted and tabulated. Extracted data included sample 
characteristics, type of analysis, relevant measures, main findings, 
demographics and information for quality assessment. The extraction process 
was completed independently by EB and any disagreements were resolved 
through discussion of the study with TC. It was decided that abstracts without 
full articles would be included given that many met inclusion criteria and 
appeared relevant to the research question.   
2. 4. Synthesis 
 
A narrative synthesis was conducted in line with previously described 
methods (Popay et al., 2006). Full reference information for included studies 
can be found in Table 1 and 2 and appendix C. Factors relating to anxiety 
were grouped into overarching conceptually or thematically related categories. 
The importance of each factor was accounted for by combining a count of the 
studies that identified or did not identify significant relationships while 
considering their methodological quality. Patterns in the data were examined 
and potential sources of heterogeneity between studies were explored 
including moderators of results such as sample size. Discrepancies, 
uncertainties and unanswered questions within the studies were also 
analysed.  
 
Table 1: Cross Sectional Studies 
Authors, 
Year 
Multi
-
Cent
re 
Type of 
MS 
Measure 
of 
anxiety 
Other 
measures 
used 
Gender/A
ge 
Full 
paper 
Eligibil
ity 
Criteri
a 
Specif
ied 
Powe
red 
Recruitm
ent 
strategy 
Akbar, N., et 
al. (2011) no 
Definite 
MS HADS 
MSNQ, NEO-
FFI,  
81 
females 
/27 
males av. 
45 years yes yes no 
Conveni
ence 
sampling 
Al-Asmi, A., 
et al. (2013) no 
Definite 
MS 
(McDona
ld 
criteria) HADS EDSS 
41 
females/
16 
males. 
av. 31.4 
years  yes yes no 
Consecu
tive  
Aloulou, J., 
et al. (2011) no 
Definite 
MS HADS TAS-20 
18 
females 
/13 
males av. 
39 years.  no yes n/s n/s 
Anhoque, C. 
F., et al. 
(2011) no 
14 
RRMS, 3 
SPMS, 2 
PPMS  BAI BDI 
14 
females 
/5 males. 
av. 37 
years.   yes yes no 
Consecu
tive  
Askari, F., et 
al. (2014) no 
142 
RRMS, 
38 
SPMS BAI BDI, EDSS 
151 
females 
/29 
males, 
av. 32.4 
years yes yes  no 
Consecu
tive  
Bamer, A. 
M., et al. 
(2008) yes 
Definite 
MS HADS PHQ-9 
1034 
females/
237 
males.  no n/s n/s n/s 
av. 50.9 
years 
Beier, M., et 
al. (2013) n/s  
Definite 
MS PHQ-A 
None 
Specified 
421 
females/
92 males 
female no n/s n/s n/s 
Beiske, A. 
G., et al. 
(2008) yes 
Clinically 
Definite 
MS 
(without 
severe 
cognitive 
impairm
ent, 
psychiatr
ic 
impairm
ent or 
other 
serious 
disabling 
disease) HSCL-25 
PASAT, MS-
FS 
94 
females / 
46 males 
av. 30.9 
years yes yes no 
Consecu
tive  
Bogart 
(2015) Yes 
Self-
report 
diagnosi
s MS HADS 
Disability 
Personal 
Identity 
Scale, ADL 
48 
females, 
58 males 
av.=58.3 
years Yes Yes No 
convenie
nce 
Brajkovic, L., 
et al. (2009) no 
Definite 
MS HADS 
MSQLI, 
COPE 
51 
females/
17 males  no n/s n/s n/s 
Bruce, J. M. 
& P. Arnett 
(2009) yes 
RRMS, 
SPMS STAI 
PSWQ, 
CMDI, EDSS, 
FIS, BPI, 
SILS, SRT, 
SDMT, Visual 
Elevator 
subtest.  
42 
females/ 
8 males 
av. 46.2 
years yes yes no n/s 
Bruce, J. M., 
et al. (2009) no 
RRMS, 
SPMS STAI 
Memory 
questionnaire
, DES-11, 
NEO-FFI, 
BDI-FS, 
neuropsychol
ogical tests  
71 
females/ 
8 males. 
av. 45.4 
years yes yes no n/s 
Bruce, J. M. 
& Lynch, S. 
G. (2011) no 
MSRR, 
MSSP, 
MSPP STAI 
NEO-FFI, 
MINI, BDI-FS, 
MFIS, EDSS 
74 
females 
/11 
males. 
av. 47.12 
years yes yes no n/s 
Chalfant, A. 
M., et al. 
(2004)  yes 
MSRR, 
MSSP, 
MSPP 
Clinician 
Administ
ered 
PTSD 
scale GDS, DSQ 
45 
females 
/13 
males av. 
49.6 
years yes no no n/s 
Chalk, H. M. 
(2007) yes 
Definite 
MS BAI 
EDSS, 
CMSS, 
CAHS, SSQ, 
SWLS, CES-
D, BAI-PC, 
MHI 
266 
females 
/63 
males yes yes no 
Randomi
sed 
Chylova, M., 
et al. (2009) n/s  
Definite 
MS HADS SF-36, EDSS 
150 
female/7
3 males. 
av. 38.9 
years no n/s n/s n/s 
Cihelkova, 
S. & Bojar, 
M. (2009) n/s  
Definite 
MS BAI  
BDI II, SCL-
90, MMSE, 
EDSS 
25 
females 
/15 
males no n/s n/s n/s 
Counsell, A., 
et al. (2013) yes 
Definite 
MS - 
61.1% 
RRMS, 
HADS; 
PTSD 
Checklist MSIS-29 
99 
females/
27 
males.  yes yes no 
Randomi
sed 
17.5% 
SPMS, 
7.9% 
PPMS, 
3.2% 
PPMS, 
3.2% 
benign 
type, 
4.8% 
were 
unsure 
of type.  
av. 45.5 
years 
Curral, R., et 
al. (2011) no 
Definite 
MS HADS 
MMSE, 
Raven, MOS 
SF-36, SCL-
90, EDSS 
35 
females 
/13 
males no n/s n/s n/s 
Da Silva, A. 
M., et al. 
(2011) no 
80.4% 
RRMS, 
9.9% 
SPMS, 
9.6% 
PPMS HADS EDSS, MSSS 
214 
females/ 
111 
males av. 
39.5 
years yes yes no 
Consecu
tive  
Dahl, O.-P., 
et al. (2009) yes 
Definite 
MS HADS FSS 
111 
females 
/61 
males av. 
50.1 
years yes yes no 
Conveni
ence  
Dubayova, 
T., et al. 
(2013) yes 
Definite 
MS HADS 
PCS, MCS, 
EDSS, 
UDPRS 
154 
females 
/44 
males. 
av. 67.6 
year yes yes no 
Randomi
sed 
Espinola-
Nadurille, 
M., et al. 
(2010) no 
Definite 
MS 
(McDona
ld 
criteria) - 
75.6% 
RRMS, 
18.9% 
SPMS, 
5.4% 
PPMS HADS 
DSM, 
MADRS 
24 
females / 
13 males 
av. 
36.3year
s yes yes no 
Consecu
tive  
Etesam et al 
(2016) 
Yes n/s HADS DDI, EDSS n/s No No No n/s 
Farrell, E., et 
al. (2011) no 
Definite 
MS HADS MSNQ n/s  no n/s n/s n/s 
Feinstein, A., 
et al. (1999) no 
Definite 
MS 
(Posars 
criteria) HADS GHQ-28 
107 
females 
/45 
males av. 
44.98 
years yes yes no 
Consecu
tive  
Fisk, J. D., et 
al. (2014) yes 
Definite 
MS HADS 
EDSS, HUI, 
HRQoL, D-
FIS 
714 
females/ 
235 
males av. 
48.6 
years no n/s n/s n/s 
Foroughipou
r, M., et al. 
(2012) no 
Definite 
MS Y-BOCS EDSS DSM 
84 
females/ 
28 
males. 
av. 31.9 
years yes yes no 
Consecu
tive  
Fruhwald, 
S., et al. 
(2001) no 
Definite 
MS ZARS 
EDSS, 
MMSE, 
ZDRS 
57 
females/ 
17 
males. 
av. 39.8 
years 
yes 
(Germ
an) yes no n/s 
Garfield, A. yes Definite HADS EDSS, GHQ- 41 yes yes no Randomi
C. & Lincoln, 
N. B. (2012) 
MS- 35 
MSRR, 
10 
MSPP, 
20 
MSSP, 3 
Benign.  
12, GNDS, 
MHLC, 
MSSS,  
females / 
27 males 
av.  50 
years 
sed 
Glanz, B. I., 
et al. (2012). no RRMS STAI 
MSQOL-54, 
CESD, MFIS, 
STAI, SDMT 
287 
females/ 
90 
males. 
av. 45.4 
years  yes yes no 
Consecu
tive  
Goretti, B., 
et al. (2014).  yes RRMS STAI BRB, BDI 
140 
females / 
50 males 
av. 37.5 
years yes yes no 
Consecu
tive  
Grech et al 
(2015) No 
RR or 
SPMS 
(McDona
ld 
criteria) STAI 
BDI-II, 
MSQOL-54, 
Daily Hassles 
Scale, 
measures of 
cognition 
83 
females, 
24 men 
av.=48.8 
years Yes Yes No 
Conveni
ence 
Hakim, E. A., 
et al. (2000). yes 
Definite 
MS HADS EDSS, MI 
Male: 
female 
ratio- 
1:2.1. av. 
48.3 
years yes yes no 
Consecu
tive  
Harding, K. 
E., et al. 
(2012).  n/s  
 50 
RRMS, 
39 
SPMS. GHQ30 
EDSS, 
GHQ30 
80 
females / 
22 males no n/s n/s n/s 
Ionescu, P., 
et al. (2012).  n/s  
Definite 
MS HAM-A 
HAM-D, 
EDSS, QOL, 
IADL n/s  no n/s n/s n/s 
Iriarte, J., et 
al. (2000). no 
Definite 
MS HAM-A 
FDS, FSS, 
HRSD EDSS 
105 
females / 
50 
males. 
av. 32.6 
years yes yes no 
Consecu
tive  
Janssens, 
A., et al. 
(2003). yes 
Definite 
MS HADS SF-36, IES 
71 
females/ 
30 
males. 
av. 37.5 
years yes yes no n/s 
Janssens, 
A., et al. 
(2004).  yes 
Definite 
MS HADS EDSS, IES 
71 
females/ 
30 
males. 
av. 37.5 
years yes yes no n/s 
Jones, K. H., 
et al. (2012) yes 
14.4% 
PPMS, 
61.7% 
RRMS, 
9.4% 
SPMS, 
14.5% 
unsure HADS 
None 
specified 
2941 
females/ 
1237 
males. 
av. 50.9 
years yes yes no 
Conveni
ence  
Jones, K. H., 
et al. (2013) yes 
Definite 
MS HADS 
MSIS-29, 
EQ5D n/s  no n/s n/s n/s 
Jones, S. M. 
& Amtmann, 
D. (2014) yes 
Definite 
MS - 
58.8% 
RR, 
11.1% 
PP, 20% 
SP, 
1%PR PROMIS 
Neuro-QOL, 
EDSS 
280 
females/
125 
males av. 
52.68 
years yes yes no 
Conveni
ence  
Jones, K. H., 
et al. (2014) yes 
Definite 
MS- HADS MSIS-29 
3211 
females/ yes yes no 
Conveni
ence  
14.8% 
PPMS, 
62.1% 
RRMS, 
8.1% 
SPMS, 
14.9% 
unsure 
1305 
males. 
av. 50.7 
years 
Jopson, N. 
M. & Moss-
Morris, R.  
(2003) yes 
Definite 
MS HADS 
SIP-68, FSS, 
RSES, IPQ-R 
131 
females/ 
37 
males. 
av.  56.2 
years yes yes no 
Conveni
ence  
Julian, L. J. 
& Arnett, P. 
A.  (2009) yes 
Definite 
or 
probable 
MS 
(Posar 
criteria) STAI 
Neuropsychol
ogical 
measures of 
executive 
functioning, 
CMDI 
61 
females/
16 
males. 
av. 46.58 
years,  yes yes no 
Conveni
ence  
Karadayi, H., 
et al. (2014) no 
Definite 
MS 
(McDona
ld 
criteria) HAM-A 
GAF, FSS, 
EDSS 
MMSE, 
Cognitive 
measures 
21 
females/ 
10 males 
av. 38.3 
years yes yes yes n/s 
Kehler, M. D. 
& 
Hadjistavrop
oulos, H. D. 
(2009) yes 
Definite 
MS HADS CHIP, GNDS 
201 
females/ 
45 
males. 
av. 41.82 
years yes yes no 
Conveni
ence 
Kikuchi, H., 
et al. (2013) yes 
Definite 
MS NAS-J EDSS, FAMS 
118 
females / 
45 males 
av. 31.9 
years yes yes no n/s 
Korostil, M. 
& Feinstein, 
A. (2007) no 
Definite 
MS HADS 
BSS, SSSI, 
Neuropsychol
ogical 
Screening 
Battery 
104 
females/ 
36 
males. 
av. 43.9 
years yes yes no 
Consecu
tive  
Kostaras, P., 
et al. (2008) n/s  
Definite 
MS STAI SDMT, BDI n/s no n/s n/s n/s 
Kraft, G. H., 
et al. (2012) no 
Definite 
MS PROMIS 
Quality of life 
indicator n/s no n/s n/s n/s 
Krokavcova, 
M., et al. 
(2010) yes 
Definite 
MS HADS SF-36, EDSS 
122 
females/ 
62 
males. 
av. 40.5 
years yes yes no 
Conveni
ence  
Labuz-
Roszak, B., 
et al. (2007) no 
n/s 
conferen
ce paper HADS 
FSS, ESS, 
AIS, MADRS 
87 
females 
/35 
males av. 
37.7 
years  no n/s n/s n/s 
Leonavicius, 
R. & 
Adomaitiene, 
V. (2013) no 
Definite 
MS. 
Progress
ive- 182, 
RRMS- 
130  HADS 
EDSS, ICD-
10 
196 
females 
/116 
males. 
av. 42.01 
years yes yes no n/s 
Leonavicius, 
R. & 
Adomaitiene, 
V.  (2011) yes 
MSRR, 
Progress
ive MS HADS 
EDSS, ICD-
10 
187 
females 
/83 
males av. 
42.42 
years no n/s n/s n/s 
Leonavicius, 
R. & 
Adomaitiene, 
V. (2014) no RRMS HADS 
MOSS, 
HRQoL 
86 
females/ 
51 
males. 
av. yes yes no n/s 
42.01yea
rs 
Lester, K., et 
al. (2007) no 
MSRR, 
MSPP, 
MSSP HADS 
EDSS, MSIS-
29, Self-
efficacy for 
managing 
chronic 
disease, 
Neuropsych 
screening 
questionnaire 
62 
females/
18 
males. 
av. 44 
years yes yes no n/s 
Levinthal, D. 
J. & 
Bielefeldt, K. 
(2014) no 
Definite 
MS HADS 
MSIS-29, 
PAGI-SYM, 
PAGI-QOL, 
PHQ-15 n/s  no n/s n/s n/s 
Liu, X. J., et 
al. (2009) no 
Definite 
MS SCL-90 
LES, 
EPQ,SSRS 
26 
females 
/15 
males. 
av. 37.44 
years yes yes no 
Consecu
tive  
Lopes, J., et 
al. (2012) n/s  
Definite 
MS HADS EDSS, FSS 
88 
females/
31 
males. 
av. 42 
years no n/s n/s n/s 
Maia, D., et 
al. (2011) n/s  
Definite 
MS HADS 
LNNB, FACE-
111 
25 
females no n/s n/s n/s 
Marrie, R. 
A., et al. 
(2013) yes 
Definite 
MS 
ICD 
Diagnosi
s.  ATC 
3006 
females/
1186 
males  yes yes no 
Consecu
tive  
Medin, K. L., 
et al. (2014) n/s  
Definite 
MS 
Determin
ed by a 
psychiatr
ist 
None 
Specified n/s  no n/s n/s n/s 
Middleton, L. 
S., et al. 
(2006) no 
Definite 
MS 
(McDona
ld 
criteria) SAS 
Cognitive 
tests, CFQ, 
FFS, CES-D, 
EDSS 
163 
females / 
58 males 
av. 44.8 
years yes yes no 
Consecu
tive  
Milanlioglu, 
A., et al. 
(2013) n/s 
RRMS 
and 
SPMS POMS EDSS, COPE 
36 
females 
/14 
males yes yes no 
Consecu
tive  
Milinis, K., et 
al. (2014) yes 
Definite 
MS HADS 
WHOQOL-
BREF, 
LMSQOL, 
WHODAS, 
MSSS-88, 
NRS 0-10, 
NFI-MS, NPS n/s  no n/s n/s n/s 
Miljatovic, A. 
M. (2013) no 
Definite 
MS HAM-A 
HAMD-17, 
EDSS n/s  no n/s n/s n/s 
Mills, R. J. & 
Young, C. A. 
(2011) yes 
Definite 
MS HADS 
NFI-MS, 
ESS, MSIS-
29 
451 
females/ 
184 
males av. 
46.6 
years yes yes no n/s 
Montel, S. R. 
& Bungener, 
C.  (2007) no 
Definite 
MS 
(Posars 
criteria) HAM-A 
MINI, 
MADRS, 
EHD, 
FABWCC, 
CHIP, SEP59 
89 
females 
/46 
males. 
av. 44 
years yes yes no n/s 
Morrow, S. 
A., et al. 
(2014) no 
Newly 
diagnose
d HADS FSS, BDIFS 
70 
females/
26 
males. 
av. 36.9 
years  no n/s n/s n/s 
Nicholl, C. 
R., et al. no 
Definite 
MS- HADS 
GHQ, EADL, 
CORE, BSI, 
70 
females/ yes yes no 
Consecu
tive  
(2001) 14% 
MSRR, 
45% 
MSPP, 
19% 
MSPP 
GNDS, BDI 26 
males. 
av. 48.97 
years 
Niino, M., et 
al. (2012) n/s  
Definite 
MS NAS-J EDSS, FAMS n/s  no n/s n/s n/s 
Noy, S., et 
al. (1995) yes RRMS HAM-A 
HRSD, 
Hackett-
Cassem 
Denial Scale, 
MAACL-R, 
EDSS 
15 
females 
/5 males. 
av. 41.8 
years yes yes no 
Consecu
tive  
Ostacoli, L., 
et al. (2013) no 
Definite 
MS- 
90.8% 
MSRR, 
3.02% 
MSPP, 
6.9% 
MSSP HADS 
IES-R, DSM, 
FSS 
164 
females / 
68 males 
av. 41.29 
years yes yes no 
Consecu
tive  
Paredes, S. 
& Kirchner 
Nebot, T.  
(2012) yes 
Definite 
MS 
SCL-90-
R 
(Spanish
) SCL-90-R 
62 
females 
/28 
males. 
av. 38.58 
years no n/s n/s n/s 
Pfaff, L., et 
al. (2014) n/s  RRMS HAM-A EHD, TAS 20 
16 
females no n/s n/s n/s 
Pieper, L., et 
al. (2012) yes 
Definite 
MS DSM-IV 
UNDS, LOT-
R n/s  no n/s n/s n/s 
Poder, K., et 
al. (2009) no 
Definite 
MS 
SPIN, 
HADS HUI, EDSS 
201 
females/ 
44 
males. 
av. 46.1 
years yes yes no 
Consecu
tive  
Poder, K., et 
al. (2007) no 
Definite 
MS SPIN,  EDSS, HUI 
216 
females/ 
49 males  no n/s n/s n/s 
Reade, J. 
W., et al. 
(2012) yes 
66% 
RRMS, 
12% 
PPMS, 
9% 
SPMS, 
13% 
other MHI 
MSQOL-54, 
MOS 
112 
females/ 
33 males  yes yes no 
Randomi
sed 
Roy Bellina, 
S., et al. 
(2010) n/s 
Definite 
MS HAM-A 
IPQ-R, BDI, 
TAS-20  
26 
females 
/6 males. 
av.  40 
years no n/s n/s n/s 
Roy-Bellina, 
S., et al. 
(2009) n/s 
Definite 
MS STAI 
EDSS, 
MHKC, SSQ, 
WCC, IPQ-R, 
BDI-11 
34 
females 
/11 
males av. 
45 years no n/s n/s n/s 
Sarisoy, G., 
et al. (2013) no 
Definite 
MS STAI 
SCL-90-R, 
BDI, PSQI, 
Padua 
Inventory, 
SES, EATS-
26, EDSS 
56 
females 
/20 
males av. 
37.84 
years yes yes no 
Conveni
ence 
Schwartz, C. 
E., et al. 
(1996) no 
Definite 
MS 
Anxiety 
subscale 
on AIMS 
MAF, EDSS, 
SIP, Rao 
cognitive 
battery, the 
Trailmaking 
Test, 
depression 
and social 
activity 
limitations 
101 
females 
/38 
males av. 
43.06 
years yes yes no Inclusive  
subscales 
from AIMS, 
Ryff 
Happiness 
Scale.  
Shabani, A., 
et al. (2007) yes 
Definite 
MS 
DSM 
interview 
None 
Specified 
45 
females 
/40 
males av. 
47. 6 
years yes yes no 
Randomi
sed 
Sidorenko, 
T., et al. 
(2010) no 
Definite 
MS HADS EDSS n/s  no n/s n/s n/s 
Silva, A., et 
al. (2009) n/s  
171 
RRMS,2
5 SPMS, 
24 
PPMS  HADS 
EDSS, 
MMSE 
150 
females 
/81 
males. 
av. 39.94 
years no n/s n/s n/s 
Silva, A. M., 
et al. (2011) n/s 
Definite 
MS 
(minimu
m 10 
years 
disease 
duration) HADS EDSS, FAMS 
103 
females 
/56 
males av. 
44.45 
years no n/s n/s n/s 
Simpson, R. 
J., et al. 
(2014) yes 
Definite 
MS 
Clinician 
recordin
g 
None 
Specified 
2766 
females/
1060 
males. 
av. 53.4 
years yes yes no  
Consecu
tive  
Smith, S. J. 
& Young, C. 
A. (2000) no 
Definite 
MS HADS 
BDI, MRS, 
two visual 
analogue 
scales. 
61 
females 
/88 
males av. 
46 years yes yes no 
Consecu
tive  
Spain, L. A., 
et al. (2007) yes 
Definite 
MS 
(Posars 
criteria)- 
54% 
MSRR, 
30% 
MSSP, 
10% 
MSPP, 
6% 
intermed
iate 
subtype.  HADS 
EDSS, 
SDMT, IPQ, 
SF-36 
458 
females/
122 
males. 
av. 46.7 
years yes yes no 
Conveni
ence  
Stenager, E., 
et al. (1994) no 
Definite 
MS 
(Posars 
criteria) STAI 
EDSS, 
measures of 
cognitive 
impairment.  
52 
females 
/42 
males av. 
42. 6 
years yes yes no n/s 
Suh, Y., et 
al. (2010) yes 
Definite 
MS HADS PDDS 
62 
females/ 
34 males 
av. 48.6 
years yes yes no 
Conveni
ence  
Szilasiova, 
J., et al. 
(2011) no 
Definite 
MS- 
77.2% 
MSRR, 
18.4% 
MSSP, 
4.4% 
MSPP HADS 
FSS, SF-36, 
EDSS 
82 
females/ 
32 
males. 
av. 36.1 
years yes yes  no 
Consecu
tive  
Tadic, D. & 
Dajic, V. 
(2013) no 
Definite 
MS 
(McDona
ld HAM-A 
EDSS, 
MSQoL-54, 
HDRS 
28 
females/ 
22 
males. yes yes no n/s 
Criteria) av. 41.2 
years 
Tan-
Kristanto et 
al (2015) Yes 
Definite 
MS 
(McDona
ld 
criteria) DASS 
EDSS, RSA, 
MSSE, Brief 
COPE 
117 
women, 
12 men 
av=38.41 
years Yes Yes No 
convenie
nce 
Theaudin et 
al (2016) Yes 
Definite 
MS 
(Posar 
and 
McDonal
d 
criteria) HADS EDSS 
489 
females/ 
222 
males av. 
44.8 
years yes yes no 
consecut
ive 
Thornton, E. 
W., et al. 
(2006) no 
Definite 
MS HADS 
WQMS, 
PSQW, 
SESMS 
27 
females / 
12 males 
av. 48.3 
years yes yes no 
Randomi
sed 
Tsivgoulis, 
G., et al. 
(2007) yes RRMS STAI BDI, EDSS 
56 
females/ 
30 
males. 
av. 39 
years yes yes no 
Consecu
tive  
Uca et al 
(2016) No 
RRMS 
(McDona
ld 
criteria) 
SCID-
I/CV 
EDSS, SCID-
II/CV 
96 
females, 
15 males 
av. 35.1 
years yes yes no n/s 
Uguz, F., et 
al. (2008) no 
RRMS 
(42 in 
exacerb
ation 
phase, 
32 in 
remissio
n phase) DSM EDSS 
50 
females/ 
24 males 
av. 34.57 
years yes yes no 
Consecu
tive  
Van Der 
Hiele, K., et 
al. (2014) yes 
RRMS 
patients HADS 
SF-36, BADS 
DEX, FIS 
39 
females / 
5 males. 
av. 37.2  
years yes yes no 
Consecu
tive  
Van Der 
Hiele, K., et 
al. (2010)  yes 
Benign, 
MSRR, 
MSSP, 
MSPP HADS 
BADS-DEX, 
SCWT, 
WCST, EDSS n/s  no n/s n/s n/s 
Van der 
Hiele, K., et 
al. (2012) yes 
Benign, 
MSRR, 
MSSP, 
MSPP HADS 
SF-36, FIS, 
EPCL 
392 
females/ 
138 
males. 
av. 48.3 
years yes yes no 
Conveni
ence  
Van der 
Hiele, K., et 
al. (2012) yes 
Benign, 
MSRR, 
MSSP, 
MSPP HADS 
BADS, EPCL, 
UCL, BAD 
DEX, 
cognitive and 
neuropsych 
assessments 
86 
females/ 
28 males 
av. 50.2 
years yes yes no 
Conveni
ence  
Visser, L. H., 
et al. (2009) n/s  
Definite 
MS HADS 
BADS-DEX, 
DIP, CERQ, 
FIS, AMS, 
UCL, SCL-R-
90 n/s no n/s n/s n/s 
Voiticovschi-
Iosob, C. & 
Moldovanu, 
I. (2013) n/s  
Definite 
MS STAI 
BDI, SF-36, 
Structured 
pain 
questionnaire n/s  no n/s n/s n/s 
Vuger-
Kovacic, D., 
et al. (2007) no 
Definite 
MS CCEI 
Locus of 
control 
Inventory n/s yes yes no n/s 
Weisbrot, D., 
et al. (2012) n/s  
Definite 
MS K-SADS 
PedsQL, 
CGAS 
29 
females/ 
16 
males. no n/s n/s n/s 
av. 15.7 
years 
White, C. P., 
et al. (2008)  yes 
Definite 
MS 66% 
RRMS, 
12% 
PPMS, 
9% 
SPMS, 
13% 
unsure 
of type MHI MFIS, MHI  
75 
females/ 
26 
males. 
av. 50 
years yes yes no 
Randomi
sed 
Ziegler, K., 
et al. (2010) n/s  
Definite 
MS DSM-IV  CAR n/s  no n/s n/s n/s 
Zorzon, M., 
et al. (2001) no 
Definite 
MS HADS DSM 
62 
females / 
33 males 
av. 39.5 
years yes yes no 
Consecu
tive  
 
Table 2: Prospective Studies 
Authors, 
Year 
Multi-
Centr
e 
Type of 
MS 
Measur
e of 
anxiety 
Other 
measure
s used 
Gender/A
ge 
Full 
pape
r 
Eligibilit
y 
Criteria 
Specifie
d 
Powere
d 
Recruitme
nt strategy 
Bianchi, V., 
et al. (2014) no RRMS HAM-A 
WCQ, 
HAM-D 
30 
females / 
9 males 
av. 28.8 
years yes yes no 
Consecutiv
e  
Brown, R. 
F., et al. 
(2009) yes 
Definite 
MS STAI 
EDSS, 
SEFCI, 
LEDS, 
FIS, BDI, 
WOCQ, 
LOT, 
MHLC, 
SSQ, 
PSQI 
81 
females / 
101 males 
av. 42.6 
years yes yes no n/s 
Burns, M. 
N., et al. 
(2013) yes 
MSRR, 
MSSP HADS 
CES-D, 
MINI 
82 
females/ 
17 males. 
av. 42.7 
years yes yes no 
Randomise
d 
Christodoul
ou, C., et al. 
(2009) yes 
28 
MSRR, 
10 MSSP STAI 
CESD, 
CMDI, 
PANAS, 
FSS, 
AES, MS 
cognitive 
batteries, 
EDSS 
22 
females/ 
16 males. 
av. 45.5 
years yes yes no n/s 
Dalos, N. 
P., et al. 
(1983) no 
Definite 
MS 
GHQ-
28 None 
66 
females / 
34 males 
av. 40.4 
years yes yes no 
Consecutiv
e  
Diaz-
Olavarrieta, 
C., et al. 
(1999) no 
RRMS 
and 
Chronic 
Progressi
ve NPI 
EDSS, 
MMSE 
30 
females / 
14 males 
av. 33 
years yes yes no 
Convenien
ce  
Giordano, 
A., et al. 
(2011) yes 
Definite 
MS  HADS EDSS 
56 
females/ 
26 males. 
av. 35.2 
years yes yes no 
Randomise
d 
Hartoonian 
et al (2015) yes 
Self-
reported 
diagnosis 
HADS-
A 
EDSS, 
NRS, 
FSS, 
421 
females, 
92 males Yes Yes No 
convenienc
e 
MS PHQ-9 Av. 51 
years 
Hoang et al 
( 2016) Yes 
Definite 
MS 
ICD-10 
diagnos
is None n/s Yes Yes No 
Consecutiv
e 
Janssens, 
A., et al. 
(2006) yes 
Recently 
Diagnose
d HADS 
IES, 
EDSS 
71 
females/ 
30 males. 
av. 37.5 
years yes yes no 
Consecutiv
e  
Johnson, K., 
et al. (2012) yes 
Definite 
MS 
PROMI
S 
Neuro-
QoL  n/s no n/s n/s n/s 
McCabe, M. 
P. (2005) yes 
Definite 
MS POMS 
WHOGO
L-100, 
WOCQ 
163 
females / 
80 males 
av. 44.86 
years yes yes no 
Randomise
d 
McKay et al 
(2016) Yes 
Definite 
MS HADS 
CAGE, 
EDSS 
714female
s /235 
males Av. 
48.6 years Yes Yes No 
consecutiv
e 
Olivares, T., 
et al. (2012) n/s   
Definite 
MS HADS 
BRB, 
MSNQ-
S, FFS, 
MS-QOL 
40 
females/ 
10 males 
av. 36.8 
years no n/s n/s n/s 
Pakenham, 
K. I. & 
Samios, C. 
(2013) yes 
Definite 
MS 
DASS-
21 
AAQ, 
MAAS 
54 
females / 
15 males 
av. 42.12 
years yes yes no 
Randomise
d 
Pekmezovic
, T., et al. 
(2012) n/s   
Definite 
MS HAM-A 
HDRS, 
MSQoL, 
EDSS n/s  no n/s n/s n/s 
Potagas, C., 
et al. (2008)  no 
Definite 
MS HAM-A SRRS 
37 
females. 
av. 32.8 
years yes yes no n/s 
Solari, A., et 
al. (2010) n/s 
92% 
RRMS HADS EDSS 
56 
females/ 
26 males 
av. 35 
years no n/s n/s n/s 
Wood, B., et 
al. (2013) yes 
Definite 
MS 
(McDonal
d criteria) HADS 
FSS, 
EDSS, 
MSSS 
125 
females/ 
73 males. 
av. 48.2 
years yes yes no 
Consecutiv
e  
 
 
A box-score method was used to quantify the relationships between the 
factors associated with anxiety among PwMS (Matcham, Alib, Hotopf, & 
Chalder, 2015).  The method involved tabulating each factor and its 
relationship with anxiety, in terms of significance and direction: a positive sign 
(+) was given for a positive significant association between variables: a 
negative sign (-) for a negative significant association between variables and 
a naught (0) for no association between variables (Green & Hall, 1984). This 
table (see Table 3) also included study design (cross-sectional or prospective) 
and level of analysis (bivariate or multivariate). Thus tabulated associations 
could be synthesized alongside indicators of study quality. Data from all 
studies were included in the box-score table except those that focused 
uniquely on prevalence rates and those that focused on subtypes of anxiety 
such as OCD, Social Anxiety or PTSD. These excluded studies will be 
outlined in detail below. Data from both bivariate and multivariate models 
were included in order to retain as much data for comparison as possible.  
3. RESULTS 
3. 1. Overview 
 
The literature search yielded 6494 relevant articles (Figure 1). Removal of 
duplicates and screening of titles and abstracts left 216 articles for full-text 
screening. Full versions of these articles were obtained and reviewed against 
inclusion criteria. Eighty-five of these did not meet the eligibility criteria. The 
most common reason for exclusion was not having measured or reported 
anxiety. One hundred and thirty-one studies were deemed eligible for 
inclusion in the narrative synthesis. Fifty-two percent of the studies used the 
Hospital Anxiety and Depression Scale (HADS). In the remaining studies, 20 
other previously validated questionnaires were used or anxiety was measured 
by assessment with a clinician (see Appendix B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
(n = 6597) 
Records after duplicates removed 
(n = 297) 
Records screened 
(n =297) 
Records excluded 
(n = 81) 
Full-text articles 
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(n = 216) 
Full-text articles 
excluded, with 
reasons 
(n = 85) 
 
 
 
 
 
 
 
 
Figure 1 PRISMA flow diagram 
 
The sample size of studies (N=131) ranged from 19 to 5084 participants.  
However, the majority of studies had sample sizes of between 50 and 200 
participants. Most of the studies in the review included both men and women. 
However, within these studies women represented the majority of participants. 
Three studies only included women. Although not all studies reported the age 
of participants, in those that did, the average range was between 15.7 years 
and 50.9 years. Most studies focused on prevalence rates, cognitive 
processes, physical, social or psychological factors. An overview of all study 
characteristics for both cross-sectional (N=112) and prospective studies 
(N=19) was carried out (see Appendix C). Data were typically analysed using 
correlations or regression.  
 
Table 3: Box Analysis of Factors Associated with Anxiety for PwMS 
Category Factor CS Bivariate CS 
Multivariate 
PS 
Bivariate 
PS Multivariate 
Demographics Gender (female) ++++++++00 + +0 ++0 
 Age (younger) ++++++ ++ 0 + 
Cognitive Dysfunction ++++00 +++++000  + 
 Cognitive change    + 
 Perception of cognitive 
dysfunction 
+++ +   
 Self-reported memory 
problems 
 0 
 
  
 Illness intrusiveness  +   
 Illness representation 
(Illness identity, cyclical 
timeline and illness 
coherence) 
0 +   
 Perception of risk  +   
 Neuropsychological 
functioning 
00 0  + 
Mood Related Depression +++++++++++ ++++++++ + ++++++ 
 Suicidal thoughts +    
 Alexithymia +    
 Low Self-efficacy + ++   
 Low emotional well-
being 
+    
 Low general well-being +    
 Psychological Distress  +   
 Difficulty managing 
mood 
 +   
 Worry +    
 Stress ++ +++   
 Health worry/anxiety  ++0   
Studies included in 
qualitative synthesis 
(n = 131) 
Personality  Extroversion +    
 Neuroticism + +   
 Conscientiousness  +   
 Low optimism    + 
 Personality disorder 
(SCID-II) 
 +   
Coping Avoidance coping  ++  0 
 Accepting 
Responsibilities 
   +- 
 Mindfulness    + 
 Resilience  -   
 Distress disclosure  +   
 Planning  +   
 Positive interpretation  -   
 Use of social support - -  - 
 Emotion focused coping ++ +++  0 
 Problem focused coping -   0 
 No relaxation training    + 
 Unhealthy behaviours 
(eg. drinking to excess, 
smoking) 
+   ++ 
Physical 
functioning  
Sleep disturbances 0+ ++   
 Better health status  +-(Young)   
 Long Duration +00000-- 00-- 0 + 
 Wheelchair bound  -  0 
 Level of disability  ++++++++++00-
00 
+++++++++++
0 
00 0 
 Daily functioning - +   
 Physical activity  0   
Symptoms Number of symptoms +    
 Pain ++++0 ++   
 Fatigue ++++0 +++0 ++  
 Exacerbations/course of 
illness 
000 ++0 ++ + 
 Dyspepsia +    
 Spasticity +    
 Speech difficulties +    
Biological  Other physical health 
problem 
+(Epilepsy)    
 Frontotemporal changes   0  
 Lesion loads 0    
 Brain Volume 0    
Medical  Poor Adherence of 
medication 
+    
 Immunotherapy status    + 
 Treatment with disease 
modifying drug (DMD) 
   + 
 Number of 
hospitalisations 
 +   
Social Factors Lack of Education +- 0   
 Negative life events +   + 
 Problems in family life +    
 Few MS group activities  +   
 Lack of information on 
MS 
 +   
 Unemployment 0 ++++  - 
 Quality of life +++ +++++ ++  
 Presenteeism at work +    
 Lower social 
activity/support 
+ 0 +  
Type MS Relapsing Remitting 
Multiple Sclerosis 
(RRMS) 
0++(Women) +   
 Secondary Progressive 
Multiple Sclerosis 
(SPMS) 
++    
+ Positive association with anxiety (p<0.05); - negative association with 
anxiety (p>0.05); 0 no association with anxiety; CS (Cross-Sectional Study); 
PS (Prospective Study) 
 
 
 Elements of study quality were also examined by applying a previously used 
quality-assessment tool which was appropriate for both cross-sectional and 
prospective study designs (Matcham, Rayner, Steer, & Hotopf, 2013) (see 
Table 4). The tool was adjusted slightly and included: whether a full paper 
was available rather than just an abstract; whether anxiety was measured 
using a validated tool; whether the recruitment strategy was randomised or 
consecutive; whether the participants were recruited from multiple centres; 
whether there was a control group; whether eligibility criteria were specified 
and whether the study was adequately powered. In the case where studies 
did not report anything for a particular eligibility indicator, they were allocated 
to the no category.  
Table 4: Quality Assessment of Studies including Conference Abstracts 
Study Type Full paper 
available 
Validated 
measure of 
anxiety 
Randomised/consecutive 
recruitment strategy 
Multi-
centre 
Control 
Group 
Eligibility 
criteria 
specified 
Adequately 
powered 
Cross 
Sectional-
studies 
69.57% 94.78% 32.76% 39.13% 14.81% 65.21% 0.93% 
Prospective 
studies 
78.95% 100% 52.63% 63.15% 47.47% 78.95% 0% 
 
 
The remainder of the results section summarises and synthesizes findings 
regarding the factors associated with anxiety (grouped into thematically or 
conceptually related categories). Given the large number of studies reviewed, 
thorough discussion of individual studies is beyond the scope of this report. 
The focus is therefore on providing a broad overview of the evidence 
available, including the conceptual backgrounds of the research. The strength 
of associations are later outlined (see Appendices C). The results are 
considered under the following sections: Prevalence of Anxiety and Subtypes; 
Demographics; Cognition; Physical Functioning; Mood Related Factors; 
Personality; Social Factors and Coping. 
3. 2. Prevalence of Anxiety and Subtypes  
 
Fifty-two cross-sectional and six prospective studies in the review included 
prevalence rates. Although rates for anxiety tended to differ across studies, all 
studies reported higher rates of anxiety among PwMS in comparison to 
control groups when present. The prevalence of anxiety generally ranged 
between 4% and 57% (Montel et al, 2007; Garfield et al, 2012). In a 
prospective study, the prevalence of anxiety was 25.4% at baseline, however, 
this decreased over time after diagnosis (Wood et al, 2013).  
 
Other studies examined prevalence rates of anxiety and anxiety subtypes for 
PwMS; 11.8% was reported for GAD, 1.2% for panic disorder, 7.1% for 
specific phobias and 11.8% for OCD (Shabani et al, 2007). Another study 
reported 18.9% for GAD, 18.9% for specific phobia and 14.9% for OCD (Uguz 
et al, 2008). Furthermore, the same study found that OCD was significantly 
more common among patients experiencing a relapse compared to patients in 
the remission phase (Uguz et al, 2008). Similar to the previously mentioned 
studies, a prevalence rate of 16.1% for OCD was also reported (Foroughipour 
et al, 2012). In this study, OCD was significantly correlated with a higher level 
of disability and long duration of disease. Furthermore, biological factors such 
as cranial, cerebellar, autonomic, sensory and motor nerve involvement were 
also associated with OCD (Foroughipour et al, 2012). 
 
A prevalence rate of 16% was reported for PTSD in PwMS (Chalfant et al, 
2004). Higher level of disability and having another health condition were both 
significantly related to these symptoms (Counsell et al, 2013). Furthermore, a 
prevalence rate of 24% was reported for PTSD that was associated with MS 
diagnosis. These patients showed significantly lower self-efficacy and social 
support (Ziegler et al, 2010). Level of education, GAD and depression were 
also reported as significant determinants of PTSD (Ostacoli et al, 2013).  
 
Two studies that specifically focused on clinically significant social anxiety 
reported prevalence rates of 29.8% and 30.6% respectively for PwMS (Podor 
et al, 2014; Podor et al, 2009). Half of these patients with social anxiety had 
GAD and a quarter had depression. Severity of social anxiety symptoms was 
associated with reduced health-related quality of life and was not related to 
neurological disability.  
3. 3. Demographics 
 
The eleven cross-sectional and six prospective studies that focused on 
gender differences associated with anxiety varied. Many studies found 
females were significantly more anxious than males at bivariate level (Dahl et 
al, 2009; Feinstein et al, 1999; Da Silva et al, 2011) and multivariate level 
(Theaudin et al, 2016; Wood et al, 2013; Chalk, 2007; Solari et al, 2010). 
Similarly, it was found that being female was an independent predictor of 
anxiety at multivariate level (Giordano et al, 2011). However, other bivariate 
studies found no gender differences for those who reported high levels of 
anxiety (Anhoque et al, 2011; Diaz-Olavarrieta, 1999; Hakim et al, 2000; 
Paredes et al, 2012). One study found slightly higher anxiety levels amongst 
men (31.1%) in comparison to women with MS (29.7%) (Dahl et al, 2012).  
 
Seven cross-sectional and two prospective studies in this review investigated 
the relationship between anxiety and age. Many studies found younger age 
was associated with anxiety symptoms (Wood et al, 2013; Hakim et al, 2000; 
Beiske et al, 2008; Leonavicius et al, 2013). However, three studies found no 
evidence for increased levels of anxiety among younger PwMS (Diaz-
Olavarrieta et al, 1999; Espinola-Nadurille et al, 2010; Harding et al, 2012).   
3. 4. Cognition 
 
Many studies found that cognitive dysfunction (deficits in thinking, 
remembering, and reasoning) was significantly correlated with increased 
anxiety (Farrell et al, 2011; Akbar et al, 2011; Bamer et al, 2008; Bruce et al, 
2009; Visser et al, 2009). Anxiety was also negatively correlated with self-
awareness of cognitive dysfunction (Grech et al, 2015; Van der Hiele et al, 
2010; Van der Hiele et al, 2012). Although, self-reported memory problems 
did not predict anxiety (Bruce et al, 2010), anxiety was found to independently 
predict cognitive performance (Julian et al, 2009). Another study found that 
anxiety predicted perceptions of global cognitive functioning but not objective 
cognitive performance (Middleton et al, 2006). A prospective study found that 
anxiety was a significant predictor of cognitive change over time 
(Christodoulou et al, 2009). Despite these findings, other studies found no 
association between anxiety and cognitive dysfunction (Middleton et al, 2006; 
Goretti et al, 2014; Kostaras et al, 2008). Furthermore, anxiety was found to 
have no association with perception of disability (Smith et al, 2000). However, 
others found patients' illness representations were a significant predictor of 
anxiety (Jopson et al, 2003) and higher perception of two-year risk of 
wheelchair dependence was significantly related with high levels of anxiety 
(Janssens et al, 2004).  
 
Neuropsychological performance, which examines cognitive, motor, 
behavioural, linguistic, and executive functioning, failed to reveal significant 
correlations with anxiety in both cross-sectional and prospective studies 
(Bruce et al, 2009; Maia et al, 2011; Olivares et al, 2012).  
3. 5. Physical Functioning 
 
Twenty-eight studies investigated the association between level of disability 
and anxiety symptoms; eighteen of these reported a significant relationship 
between high level of disability and high level of anxiety at either bivariate or 
multivariate level (Tan-Kristanto et al, 2015; Anhoque et al, 2011; Askari et al, 
2014; Curral et al, 2011; Ionescu et al, 2012, Sarisoy et al, 2013). Multiple 
linear regression analysis showed that depression and disability level were 
independent predictors of anxiety (Askari et al, 2014). A strong correlation 
was found between the number of symptoms inherent to the disease and 
anxiety (Roy-Bellina et al, 2010).  Bogart (2015) also reported that disability 
identity; affirming one’s status as a person with a disability, was a predictor of 
lower anxiety among PwMS.  
 
Symptoms and disease related factors 
In total, fourteen studies investigated the relationship between duration of 
illness and anxiety and in general findings were inconsistent. However, a 
recent study with a cohort of 5084 MS patients found that PwMS have an 
increased risk of anxiety during both the pre-diagnostic and post-diagnostic 
period compared to controls (Hoang et al, 2016). Furthermore, a prospective 
study with 513 PwMS reported that anxiety at time one predicted anxiety four 
months later while controlling for demographic and disease related variables 
(Hartoonian et al, 2015).  
 
The seven studies that investigated the relationship between pain and anxiety 
found a significant relationship between high levels of pain and anxiety at 
bivariate and multivariate level, with the exception of one cross-sectional 
bivariate study. Similarly, ten studies examined the relationship between 
anxiety and fatigue; all of these reported significant results either at bivariate 
or multivariate levels with the exception of two cross-sectional studies. Four 
studies examined the relationship between sleep disturbance and anxiety. 
Two multivariate studies and one bivariate study found strong correlations 
(Bamer et al, 2008; Leonavicius et al, 2014). However, one bivariate study 
found no association between anxiety and sleep disturbance (Bruce et al, 
2009).   
 
Eight studies examined the relationship between course of illness or relapses 
and anxiety. The four prospective studies showed that number of relapses 
over time could significantly increase anxiety levels (Brown et al, 2009; Dalos 
et al, 1983; McCabe, 2005; Potagos et al, 2008).  
 
A range of biological factors was investigated in relation to anxiety. Anxiety 
did not correlate significantly with any of the measures of regional and total 
lesion loads and brain volume (Zorzon et al, 2002). Similarly, anxiety had no 
significant association with frontotemporal changes measured by MRI (Diaz-
Olavarrieta, 1999).  
 
Medical Factors and treatment 
Adherence is often a key issue for those who are chronically ill. One study 
reported a significant relationship between high level of anxiety and low level 
of adherence at bivariate level (Sidorenko et al, 2010). Anxiety levels were 
also significantly associated with lower levels of social support (Reade et al, 
2012). Knowledge of disease information was found to improve anxiety levels 
(Niino et al, 2012). 
 
3. 6. Mood Related factors 
 
Overall, nineteen cross-sectional and eight prospective studies investigated 
the relationship between anxiety and depression. Strong positive correlations 
were consistently found between anxiety and depression in the cross-
sectional studies (Dahl et al, 2009; Smith et al, 2000; Aloulou et al, 2011; 
Garfield et al, 2012; Anhoque et al, 2011; Espinola-Nadurille et al, 2010; 
Arnett et al, 2011; Karadayi et al, 2014; Leonavicius et al, 2011; White et al, 
2008). Furthermore, multiple linear regression analysis showed that 
depression was an independent predictor of anxiety in patients (Giordano et 
al, 2011; Anhoque et al, 2011; Bamer et al, 2008). Prospective studies have 
further shown a strong association between depression and anxiety (Solari et 
al, 2010; Brown et al, 2009; Pakenham et al, 2013).  
3. 7. Personality 
 
Both extroversion and neuroticism were strongly correlated with anxiety 
symptoms among PwMS (Liu et al, 2009). Furthermore, anxiety accounted for 
unique variance in conscientiousness (R2=.23, F=25.37, P<.001) and 
neuroticism (R2=.65, F=153.09, P<.001) at the multivariate level (Bruce et al, 
2011). A prospective study found anxiety was strongly correlated to low 
dispositional optimism at baseline (Brown et al, 2009). Recently, a study also 
found that PwMS and a personality disorder had a significantly higher 
frequency of any anxiety disorder including PTSD (Uca et al, 2016).  
3. 8. Social factors 
 
Seven studies focused on the role anxiety had on employment and job 
productivity. Presenteeism, the act of attending work when sick, was 
significantly associated with elevated levels of anxiety (Glanz et al, 2012). 
Changes in employment status after MS onset, also had a negative impact on 
anxiety levels at multivariate but not bivariate level (Kikuchi et al, 2013; Niino 
et al, 2012). Patients without anxiety were significantly more likely to be 
employed (Tan-Kristanto et al, 2015; Krokavcova et al, 2010). However, one 
study found no relationship between employment and anxiety (Van der Hiele 
et al, 2014).  
 
Significant associations were found between anxiety and negative life events, 
problems in family life and social functioning (Potagas et al 2008; Liu et al, 
2009). Mixed results were found for the relationship between anxiety and level 
of education as both low level of education and having a university education 
were significantly associated with high levels of anxiety (Shabani et al, 2007; 
Da Silva et al, 2011). Quality of life (QoL) was examined in eight cross-
sectional and two prospective studies. Anxiety was strongly associated with 
lower QoL (Dubayova et al, 2012; Fisk et al, 2014l Fruhwald et al, 2001; 
Szilasiova et al, 2011; Tadic et al, 2013; Spain et al, 2007; Olivares et al, 
2012;  Pekmezovic et al, 2012), at all levels of illness severity (Ionescu et al, 
2012).  
3. 9. Coping  
High levels of anxiety were consistently associated with emotional 
preoccupation coping (focusing on the emotional consequences of MS) (Tan-
Kristanto et al, 2015; Roy-Bellina et al, 2010; Kehler et al, 2009; Montel et al, 
2007; Roy-Bellina et al, 2009), avoidance coping (denial) (Tan-Kristanto et al, 
2015), drinking to excess (Dahl et al, 2009) and substance abuse (Milanlioglu 
et al, 2013). A recent, large, representative study found alcohol dependence 
and smoking were associated with anxiety (McKay et al, 2016). Prospective 
studies found that smoking and no previous training in relaxation exercises 
were predictors of anxiety (Brown et al, 2009). Somewhat surprisingly 
planning, acceptance and focus on emotional ventilation worsened symptoms 
(Brajkovic et al, 2009).  
 
Research examining predictors of anxiety found positive reinterpretation, 
social emotional support and humour predicted an improvement of anxiety 
symptoms. “Problem focused coping” (targeted at reducing the stressor) was 
also negatively correlated with anxiety (Roy-Bellina et al, 2009). A prospective 
study found that patients who accessed social support to cope had a 
reduction in anxiety scores in contrast to the population norm (Johnson et al, 
2012). Anxiety was also significantly associated with low levels of acceptance 
and mindfulness (Pakenham et al, 2013).  
4.DISCUSSION 
4. 1. Summary of main findings  
The results of this review suggest that anxiety is associated with a variety of 
physical, psychological, cognitive and social factors, some of which are 
amenable to change, as highlighted in table 3. Overall, the high prevalence of 
anxiety that was reported across majority of the studies for PwMS contrasted 
strongly to a prevalence rate for anxiety of 5.1% for the general population 
(Aarsland & Figved, 2007). Many studies found significant associations 
between high levels of anxiety and depression in PwMS. In one study, 
depression was found to be the most significant factor associated with anxiety 
(Garfield et al, 2012). The significance of other factors such as self-efficacy, 
level of disability and stress were diluted due to their influence in multivariate 
analysis. Although prospective studies were limited in number, one 
prospective study carried out over two years revealed that depression strongly 
predicted anxiety, and anxiety strongly predicted later depression (Brown et 
al, 2009). In many of the studies women represented the majority of 
participants. This gender imbalance is likely due to the higher prevalence of 
MS among women. It has been suggested that a gender ratio approaching 4:1 
exists which is similar to other autoimmune diseases such as rheumatoid 
arthritis (Orton et al., 2006). 
 
Anxiety and depression were predicted by a combination of unhealthy lifestyle 
behaviours (e.g. drug use, smoking) (Brown et al, 2009; McKay et al, 2016). 
Several studies suggested that various other types of coping strategies were 
linked to anxiety symptoms. PwMS were less likely to use positive and 
problem-focused strategies in comparison with the general population, and 
used avoidance and emotional preoccupation strategies more frequently 
(Goretti et al., 2009).   
Although low level of social support was associated with higher level of 
anxiety it is important to acknowledge the complex nature of social support in 
relation to health (Matcham et al., 2015): those with anxiety may have 
distorted perceptions of the availability of social support. Furthermore, 
personality factors such as neuroticism may confound associations between 
social support and health, and there are genuine cultural differences in 
perceptions of “adequate” social support (Thoits, 2011). 
 
4. 3. Methodological critique of reviewed studies 
 
Overall, despite the large number of studies relevant to this review, the quality 
of the research was disappointing. In some cases, the strengths of 
associations between anxiety-related factors were not reported, for example 
when only the abstract of the study was available.  
 
The fundamental limitation of the reviewed research was that most studies 
(112 out of 131) were cross-sectional; without prospective evidence causal 
relationships cannot be established. Nevertheless, understanding the factors 
associated with anxiety provides an insight into issues that could be tackled 
through psychological interventions, leading to better outcomes.  
 
Another problem was that some studies used small sample sizes and were 
therefore underpowered to detect relationships, or prevents the application of 
positive findings to larger populations (Kothari, 2004). Inadequate reporting of 
participant characteristics made it difficult to interpret study findings or make 
assumptions about generalisability. Some studies failed to report important 
demographic data or recruitment strategies which prevented the reporting of 
descriptive statistics for demographic data and information for quality 
assessment.   
 
Other significant weaknesses were linked to the measurement of anxiety and 
factors associated with anxiety. The studies relied primarily on participant self-
report measures. This may mean that results were influenced by shared-
method variance which could threaten the validity of conclusions made 
regarding the relationships between measures (Huang, Liao, & Chang, 1998). 
In some studies a rating scale for anxiety was included alongside many other 
psychometric measures, therefore formal Diagnostic and Statistical Manual of 
Mental Disorders, fifth edition (DSM-V) diagnoses could not be made. The 
use of scales can cause difficulty with interpreting data and making accurate 
assumptions. Screening tools for anxiety disorders in comparison to 
depression can be particularly problematic because different kinds of anxiety 
disorders generally have more heterogeneous symptoms than different types 
of depressive disorders. In addition to this, normal expressions of anxiety in 
clinical samples generally exhibit a greater overlap with anxiety symptoms 
shown by patients that are diagnosed with an anxiety disorder (Rose & 
Devine, 2014). It is important to consider that in some studies anxiety was not 
the primary focus of research and therefore it was difficult to interpret findings. 
However, we felt that it was important to include these studies to ensure this 
paper gave a comprehensive overview of the literature to date. 
 
Some studies also failed to report results in conventional formats (e.g. a 
regression analysis table including beta coefficients and p-values (American 
Psychological Association, 2009). This prevented the interpretation of results 
about the relative importance of factors associated with anxiety.  
 
4. 4. Models of understanding anxiety in the context of MS 
 
A number of theoretical models of anxiety have previously been proposed, 
including the Avoidance Model of Worry and GAD (Borkovec, 1994), the 
Intolerance of Uncertainty Model (Dugas, Letarte, Rheaume, Freeston, & 
Ladouceur, 1995), the Metacognitive Model (Wells, 1995), the Emotion 
Dysregulation Model (Mennin, Heimberg, Turk, & Fresco, 2002) and the 
Acceptance-based Model of GAD (Roemer & Orsillo, 2002). These offer 
valuable insights into the basic nature of GAD and the necessary steps for 
successful treatment (Behar, DiMarco, Hekler, Mohlman, & Staples, 2009). 
They share a common emphasis on the central importance of avoidance of 
internal experiences. However, given their general nature they do not 
specifically account for the unique worries associated with MS. The Working 
Model of Adjustment to Multiple Sclerosis (Dennison, Moss-Morris, & Chalder, 
2009) has been proposed as a provisional working model of adjustment to MS 
that incorporates many specific concerns associated with MS. Beck’s model 
of emotional disorders (Beck, 2011) can usefully be applied to people with 
anxiety in the context of MS (see figure 2). The model assumes that anxiety 
can be triggered by critical events. These events may include developing the 
disease, fear of disability or other life stressor. Subsequently, avoidance 
coping, low mood or stress and unhelpful thinking maintains the symptoms.  
 
 Figure 2: A Working Conceptual Model of Anxiety for PwMS 
 
4. 2. Clinical implications of key findings  
The findings of this review have many clinical implications. Firstly, although 
anxiety is commonly reported in PwMS, it is often not treated (Beiske et al, 
2008). It is unknown whether this is due to the failure of clinicians to diagnose 
mental health problems or whether PwMS decline treatment. We think the 
Early Life Experiences / anxiety 
prone personality 
and/or Diagnosis of MS 
Unhelpful Beliefs about Self 
(Other people are more able than 
me)  
Critical Incident 
(Being embarressed in public due to 
MS symptoms) 
Automative Negative Thoughts 
(I will never be able to manage on my own)  
Symptoms 
• Behavioural- Avoidance and Emotion Focused 
Coping, Smoking, Drinking to excess 
• Mood- Anxiety + Depression, Low Optimism, 
Low Self-efficacy, High level of Stress   
• Thoughts- Low Perception of Cognitive Ability, 
Negative Thoughts, High Perception of Risk  
• Physical- Relapses, Fatigue, Pain 
latter unlikely. Nonetheless, this review suggests the importance of detecting 
and treating anxiety when patients are first diagnosed with MS. They should 
then be monitored throughout the course of the illness.   
 
Few studies to date have specifically targeted anxiety within an MS 
population. It is difficult to know why this is the case but it may be that the 
more overt physical consequences of MS have been prioritized or it may be 
due to an over-focus on depression and cognition. One small study of 
individual cognitive behavioural therapy versus psychotherapy found a 
reduction in anxiety levels in people who received CBT (Foley, Bedell, 
LaRocca, Scheinberg, & Reznikoff, 1987). Similarly, a small study of guided 
imagery and relaxation found reduced anxiety scores in PwMS (Maguire, 
1996).  
Comorbid anxiety and depression can have important consequences for 
patients in terms of their MS, their ability to engage in treatment and their 
quality of life (Garfield et al, 2012). Although interventions targeted at 
comorbid depression and anxiety have been neglected within the MS 
literature, treatments such as trans-diagnostic interventions that use the same 
underlying treatment principles across mental disorders, have been beneficial 
for general adult populations with comorbid anxiety and depression (McEvoy, 
Nathan, & Norton, 2009). These interventions apply core CBT-based 
treatment principles and techniques such as graded exposure and cognitive 
restructuring which target the common processes underlying anxiety and 
depression, rather than targeting the symptoms of specific disorders. 
Furthermore, a systematic review of existing literature on these types of 
treatments for depression and anxiety disorders in adults found large and 
significant reductions in both anxiety and depression, and moderate 
improvements in quality of life (Newby, McKinnon, Kuyken, Gilbody, & 
Dalgleish, 2015). Previous research indicates that PwMS benefit from 
strategies that enhance self-efficacy, a transdiagnostic process (Fraser & 
Polito, 2007) (Nodhturft et al., 2000). Future research should therefore 
investigate the efficacy of psychological interventions for PwMS. 
Pharmacologically serotonin reuptake inhibitors are considered first-line 
treatment in depression comorbid with a spectrum of anxiety disorders 
(Coplan, Aaronson, Panthangi, & Kim, 2015). It has further been 
recommended that combining benzodiazepines with an SSRI can lead to 
more rapid control of anxiety and improved control of episodic or situational 
anxiety (Dunlop & Davis, 2008). There is little evidence to date on the 
pharmacological treatment of depression and anxiety specifically for PwMS. A 
Cochrane review on pharmacologic treatment of depression for PwMS 
reported only two randomised controlled trials, which both had significant 
problems within their methodology including loss of follow-up data (M.W. 
Koch, Glazenborg, Uyttenboogaart, Mostert, & De Keyser, 2011) A recent 
review indicated high antidepressant use among PwMS and suggested that 
these drugs are possibly helpful in idiopathic major depressive disorder or 
based on patient and doctor beliefs that they are beneficial (M. W. Koch et al., 
2015). Overall, it appears that large, well-controlled trials are required for 
pharmacological treatments in MS in order to establish a firm evidence base 
on their efficacy for both depression and anxiety.  
4. 5. Limitations of the review  
 
A number of limitations of this review should be considered. Firstly, due to the 
large number of studies available, only studies published in peer-reviewed 
journals were considered. It was beyond the scope of the review to examine 
unpublished studies and the “grey literature”. Unfortunately this decision may 
result in bias since unpublished studies are more likely to demonstrate no 
relationships.  
 
Secondly, due to the large number of studies, the review included only 
quantitative research (including one mixed methods study); qualitative studies 
were excluded. Although qualitative research does not generally determine 
whether one variable can influence another or conclusively establish 
relationships, qualitative research can offer rich and detailed understandings 
on the complex associations of interest.  
 
Finally, there has been no previous systematic review conducted to date on 
anxiety among PwMS. In this study, because the inclusion criteria were broad, 
the studies were vastly heterogeneous, and so not conducive to an overall 
synthesis. Furthermore, the broad inclusion criteria resulted in studies that 
had weak methodology and did not provide strong evidence of associations, 
particularly causal relationships. This review aimed to draw attention to the 
dearth of high quality evidence, improve the quality of future research and 
highlight areas in which future studies should focus on.  
4. 6. Suggestions for future research 
 
Specifically, prospective studies are needed to determine which factors 
precede or predict anxiety. Ideally, studies need to employ prospective 
designs and assess large samples of participants when MS is first diagnosed 
and thereafter. It is important that recruitment strategies are specified and 
power calculations are stated to improve the overall quality of this literature.  
 
Future studies should also examine the neuroimaging correlated of anxiety as 
has been done previously researched for depression and cognition in MS 
(e.g.(Malkki, 2015; Mrabet, Ben Ali, Kchaou, & Belal, 2014). This may 
enhance our understanding of how potential biomarkers such as structural 
brain changes relate to anxiety in PwMS.  
 
5. CONCLUSION 
This review has shown that high levels of anxiety exist among PwMS, 
highlighting the need for early intervention and treatment of anxiety 
throughout the course of MS. Anxiety in MS is associated with a number of 
physical, cognitive, social and psychological factors which have been 
conceptualized in a model of anxiety. Due to the high levels of comorbidity 
with depression, many PwMS are likely to benefit from psychological and 
pharmacological interventions targeting both anxiety and depression.  
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Appendix A: Search terms 
A search was conducted for articles published between January 1980 and 
September 2016 which examined MS-related anxiety. Search terms were 
customized to each database and combined with key word searches e.g. 
“anxiety”, “anxiety disorder”, “anxious” and terms such as “Multiple Sclerosis”, 
“MS”, “determine*”, “predict*”, “correlate*”, “relationship*”, “prevalence”, 
“intervention*”, “association*” and “outcome*”.  
 
Appendix B.  Anxiety Measures used in studies (N=122) 
 
Anxiety Measure Number of Studies 
Hospital Anxiety and Depression 
Scale (HADS) 
65 
Beck Anxiety Inventory (BAI) 4 
Patient Health Questionnaire (PHQ) 1 
Hopkins Symptom Checklist 1 
Hamilton Anxiety Scale (HAM-A) 12 
Spielberger State Trait Anxiety 
Inventory (STAI) 
15 
General Health Questionnaire (GHQ-
28)  
1 
General Health Questionnaire (GHQ-
30) 
1 
Yale-Brown Obsessive Compulsive 
Scale 
1 
Neuropsychology Inventory (NPI) 1 
Health Anxiety Inventory  2 
Profile of Mood States (POMS) 2 
Mental Health Inventory (MHI) 2 
Social Phobia Inventory (SPIN) 2 
Depression Anxiety Stress Scale 
(DASS) 
2 
Crown-Crisp Experiential Index 
(CCEI) 
1 
Nottingham Adjustment Scale (NAS) 2 
Zung Self-Rating Anxiety Scale (SAS) 1 
Zung Anxiety Rating Scale (ZARS) 
(German) 
1 
Symptom Checklist-90 (SCL-90) 
(adapted to Spanish) 
 
1 
PROMIS 3 
DSM  3 
ICD 2 
K-SADS 1 
Determined by Psychiatrist 2 
Clinician administered PTSD scale  1 
 
 
Appendix C. Results and Strengths of Associations for 
Cross-Sectional and Prospective Studies 
Cross-Sectional Studies 
 
Authors, Year 
No. 
Patients 
No. 
Controls 
Factor/s 
investigated Type analysis 
Results 
Akbar, N., et al. 
(2011) 108 0 
Cognitive 
dysfunction 
Stepwise 
linear 
regression 
model 
Anxiety was a predictor for 
cognitive dysfunction  (R
2 
= 
0.108, F = 12.4 p = 0.001) 
(measure completed by 
informant of the patient) (R
2 
= 
0.272, F = 38.93, p < 0.001) 
(measure completed by 
patient).  
Al-Asmi, A., et al. 
(2013) 57 53 Prevalence  
Chi-Square; 
ANOVA; 
Wilcoxon 
Rank test 
Prevalence = 50.8%. multiple 
sclerosis was associated with 
substantial risks of symptoms 
of anxiety (OR = 2.43; 95 % CI 
1.13, 6.82; P = 0.03). HADS 
scores on anxiety among MS 
patients were significantly 
higher (8.3 vs. 4.9) than that 
among the control group (P = 
0.04).  
Aloulou, J., et al. 
(2011) 31 0 
Disability; Age; 
Alexithymia; 
Depression 
Descriptive 
statistics and 
correlation 
analysis 
Prevalence = 52%. Anxiety 
was correlated with the level of 
disability and age of disease 
onset.  A positive correlation 
was also found between 
anxiety and alexithymia and 
anxiety and depression. (Only 
abstract available) 
Anhoque, C. F., et 
al. (2011) 19 0 
Prevalence; 
Disability 
Correlation 
analysis 
MS patients had a high 
prevalence of anxiety. The 
association between anxiety 
and level of disability was 
significant (p=0.02) (no 
strength specified).  
Askari, F., et al. 
(2014) 180 0 
Depression; Level 
of disability 
 
Multiple 
Regression 
Analysis  
Depression (b=0.61, 95% CI 
(0.53, 0.8) p=0.001) and level 
of disability (b=0.38, 95% CI 
(1, -3.3) p<0.001) were 
significant predictors of anxiety 
in PwMS.  
Bamer, A. M., et 
al. (2008) 1271 0 
Prevalence; 
Clinical variables 
Multiple 
Logistic 
Regression 
Prevalence =25%. Regression 
analysis showed that anxiety is 
associated with difficulties in 
thinking, higher depressive 
symptoms, more pain, 
increased level of stress, sleep 
problems, not using a wheel 
chair and with better health. 
(Only abstract available) 
Beier, M., et al. 
(2013) 513 0 
Measure of anxiety 
and related factors 
EFA/CFA and 
Correlations 
The reliability and validity of 
the PHQ-A as a measure for 
PwMS was supported for 
PwMS. The PHQ-A was highly 
correlated with anxiety(r = .70). 
Age (r = -.12) and duration of 
MS (r = -.14) were both 
negatively associated with 
anxiety (both p < .005). 
Women endorsed significantly 
higher anxiety than men (t 
(508) = 2.13, p = .03). There 
were also significant 
differences in anxiety between 
MS types; PwMS with SPMS 
endorsed the most anxiety 
symptoms (F (3, 496) = 55.4, p 
= .001). Individuals higher in 
anxiety also endorsed more 
depressive symptoms (.70, p < 
.001), reported higher pain 
severity (r = .40) and more 
pain interference (r = .42), (all 
p < .001). (Only abstract 
available) 
Beiske, A. G., et 
al. (2008) 140 0 Pain; Fatigue; Age 
Multiple 
Regression 
Analysis 
Pain (OR=5.120, 95%CI 
(1.087-24.122), p = 0.010), 
fatigue (OR=0.993, 95% CI 
(0.882-0.986), p = 0.039) and 
younger age at onset 
(OR=0.93, 95% CI 0.88–0.99) 
p= 0.014) were significant 
predictors of anxiety. 
OR=Odds Reduction. 
Bogart et al 
(2015) 106 0 
Disability identity, 
depression,anxiety, 
MS duration, 
demographics  
Hierarchical 
regressions 
 
37% had likely cases of 
anxiety. Stronger disability 
identity was associated with 
significantly lower anxiety and 
explained a significant 4% 
increase in variance. The 
significant predictors of anxiety 
in the final model were age, 
disability identity, and ADL. 
The final model explained 19% 
of the variance in participants’ 
anxiety. 
Brajkovic, L., et al. 
(2009) 68 0 
Prevalence, Coping 
mechanisms 
Multiple 
Regression 
Analysis 
Prevalence = 63.2% 
(symptoms of anxiety) 
Predictors improving anxiety 
were positive reinterpretation, 
social emotional support and 
humor; Predictors worsening 
anxiety were planning, 
acceptance focus on emotional 
ventilation and denial. (Only 
abstract available) 
Bruce, J. M. & P. 
Arnett (2009) 50 45 
Depression, Level 
of disability, 
Fatigue, Sleep Correlations 
High level of anxiety was 
correlated with higher levels of 
depression (r =0.73, p < .001).  
Disturbances No significant relationships 
were found between anxiety 
and disability level, overall 
fatigue, sleep disturbance, 
pain, and neuropsychological 
functioning. 
Bruce, J. M., et al. 
(2009) 79 0 
Cognitive 
impairment and 
Perceived memory 
failures. 
Stepwise 
Linear 
Regression 
PwMS reported more anxiety 
than controls (32.75 + 6.54; t 
(96) =2.59, p < .05). Self-
reported memory problems (r 
=0.50, p<.001) and higher total 
dissociation (disruption to 
cognitive processes) (r = 0.59, 
p< .001) were correlated with 
high level of anxiety. Anxiety 
did not account for unique 
variance in self-reported 
memory in the regression 
model.  
Bruce, J. M. & 
Lynch, S. G. 
(2011) 85 20 Personality 
Stepwise 
Regression 
Stepwise regression revealed 
that anxiety accounted for 
unique variance in neuroticism 
(R
2
=0.65, F=153.09, p<0.001) 
and in conscientiousness 
(R
2
=0.23, F=25.37, p<0.001).  
Chalfant, A. M., et 
al. (2004)  58 0 Prevalence PTSD 
Descriptive 
Statistics 
Nine PwMS (16%) met 
symptom criteria for PTSD. 
Chalk, H. M. 
(2007) 329 0 
Gender; RRMS 
type MANCOVA 
Females (F (1,312) =5.20, p < 
.05) and patients with RRMS 
had higher levels of anxiety (F 
(1,312)= 5.08, p <0.05).  
Chylova, M., et al. 
(2009) 223 0 Age; Health status 
Multiple 
Regression 
analysis 
Anxiety was related to worse 
physical and mental health 
status in younger MS patients, 
but not in the older ones (Only 
abstract available) 
Cihelkova, S. & 
Bojar, M. (2009) 40 0 Prevalence 
Descriptive 
Analysis 
A high prevalence of anxiety 
was detected by BAI II of 65% 
and by SCL-90 of 62 % in 
PwMS (Only abstract 
available) 
Counsell, A., et al. 
(2013) 126 0 PTSD 
Multiple 
Regression 
analysis 
Higher MS-related disability 
(b=0.15, p=0.007), having 
another health condition 
(b=2.48, p=0.005) and anxiety 
(b=1.35, p=0.000) were 
significant predictors of PTSD 
symptoms (R
2
=0.51). 
Curral, R., et al. 
(2011) 48 0 Prevalence  
Descriptive 
Statistics 
PwMS did not have 
significantly high levels of 
anxiety (Only abstract 
available) 
Da Silva, A. M., et 
al. (2011) 325 183 
Prevalence; 
Gender; Education.  
Correlation 
analysis; 
MANCOVA 
Prevalence =51%. Anxiety 
scores were significantly 
higher for women (t=4.213, p < 
0.001). Negative correlations 
were found between number of 
years of education and level of 
anxiety (r = − 0.215 and p < 
0.001). For MANCOVA no 
statistically significant 
differences were found 
between anxiety and course of 
illness. 
 
Dahl, O. P., et al. 
(2009) 172 56,000 
Gender; Duration; 
Disability 
Descriptive 
statistics and 
Among men the prevalence 
rate of anxiety was 31.1% 
correlation 
analysis 
versus 12.1% for controls (p = 
0.002). For women, the 
prevalence of anxiety was 
29.7% versus 17.4% for 
controls (p < 0.001).  Anxiety 
was not correlated with 
duration of disease or 
disability. 
Dubayova, T., et 
al. (2013) 198 142 Quality of life 
Multiple 
Regression 
Analysis 
Anxiety was a significant 
predictor for lower scores for 
quality of life in the regression 
model (b=0.38, p<0.001, 
R
2
=0.33) 
Espinola-
Nadurille, M., et 
al. (2010) 37 37 
Prevalence of 
anxiety; 
Depression 
Descriptive 
Statistics 
Prevalence = 28.6%. Levels of 
anxiety were significantly 
higher in patients with 
depressive disorders 
compared to those without 
(21.2 SD=9.91 versus 9.33 
SD=8.54, p.001). No 
significant differences 
concerning correlations 
between age, number of 
relapses, duration of illness, 
disability and anxiety were 
found. 
Etesam et al. 
(2016) 112 0 
Self-disclosure; 
Depression 
Pearson 
Correlation 
coefficient 
Multiple 
Regression 
analysis 
There was a positive and 
significant correlation among 
disease variables (level of 
disability and the number of 
times hospitalized) and anxiety 
(p<0.01.) Higher scores of 
anxiety were negatively 
associated with distress 
disclosure (p<0.01.). Multiple 
linear regression analysis 
revealed that frequency of 
hospitalization and disability 
level, predicted anxiety 
(p<0.05.) Controlling disease 
variables demonstrated 
distress disclosure as an 
independent factor to predict 
anxiety in the participants 
(p<0.05.)  
Farrell, E., et al. 
(2011) 101 0 
Prevalence; 
Cognitive 
Difficulties; 
Depression 
Correlation 
analysis 
Prevalence = 32.1%. There 
were significant correlations 
between anxiety and reported 
cognitive difficulties and 
anxiety and depression. (Only 
abstract available) 
Feinstein, A., et 
al. (1999) 152 0 
Prevalence; 
Gender 
Descriptive 
Statistics 
Prevalence =15.8%. Anxious 
patients were statistically more 
likely to be female (22/24 were 
female).  
Fisk, J. D., et al. 
(2014) 949 0 Quality of life 
Multiple 
Regression 
Analysis 
Regression analyses showed 
that anxiety was associated 
with quality of life (Only 
abstract available) 
Foroughipour, M., 
et al. (2012) 112 0 OCD 
Chi-Square 
tests 
Prevalence of OCD in patients 
with MS was 16.1%. The OCD 
was significantly associated 
with a higher level of disability 
(X-2 = 86.515, p = 0.0001), 
duration of disease (X
2
= 
9.135, p= 0.033), phenotypic 
subgroup (X
2 
= 8.970, p = 
0.029), cranial nerve 
involvement (X
2 
= 6.531, p= 
0.011), cerebellar nerve 
involvement (X
2 
= 19.390, p= 
0.0001), autonomic nerve 
involvement (X
2 
= 18.587, p = 
0.0001), sensory nerve 
involvement (X
2 
= 11.593, p = 
0.001) and motor nerve 
involvement (X
2 
= 25.652, p = 
0.0001). 
Fruhwald, S., et 
al. (2001) 74 74 Quality of life 
Mann 
Whitney-U 
tests 
There was a significant 
relationship between anxiety 
and quality of Life (Only 
abstract available in English). 
Garfield, A. C. & 
Lincoln, N. B. 
(2012) 157 0 
Prevalence; 
Difficulty with 
mood; Distress; 
Depression 
WALD Chi-
square test 
Logistic 
Regression 
Prevalence =57%. 
Experiencing difficulty with 
mood (Wald’s X
2 
(1) = 11, 
b=1.18, p= 0.001), 
psychological distress (Wald’s 
X
2 
(1) = 6.3, b=0.21, p = 0.01) 
and depression (Wald’s X
2 
(1) 
= 5.05, b=0.28, p =0.03) were 
significant predictors of 
clinically significant levels of 
anxiety (R
2
=0.46).  
Glanz, B. I., et al. 
(2012). 377 0  Presenteeism  
Correlation 
Analysis 
Presenteeism was correlated 
with anxiety (r=0.39, p<0.05). 
Goretti, B., et al. 
(2014).  190 0 
Cognitive 
Dysfunction 
Multiple 
Regression 
Analysis 
In the multivariate analysis, 
anxiety was associated with 
failure on the Symbol Digit 
Modalities Test (OR = 2.07, 95 
% CI 1.01–4.41, p = 0.05), 
There was no relationship 
between anxiety and failure on 
other neither 
neuropsychological tasks nor 
overall cognitive dysfunction.  
Grech et al (2015) 107 0 
Cognitive 
Dysfunction; stress, 
depression; Quality 
of life 
Hierarchical 
regression 
analysis  
 
Only the self- and 
independent-report variables 
significantly predicted trait 
anxiety (DEX–S: B = 
0.72,p=.008,OR=2.06;DEX–
I:B=0.41,p= .04, OR = 1.51). 
They were entered into the 
final model jointly at Step 2, 
where they significantly 
predicted trait anxiety, 
although only the DEX–S 
individually reached 
significance, B = 0.64, p = .03, 
OR = 1.89. The total model 
accounted for 29.0% of the 
variability in trait anxiety.  
Hakim, E. A., et 
al. (2000). 305 0 
Prevalence; 
Gender; Age; 
Duration; Severity 
Standardised 
Prevalence 
Ratios 
Prevalence =16%. Anxiety was 
not related to disease severity, 
duration or gender. Anxiety 
was present in 37% of patients 
who were less than 30 years 
old compared to 17% of those 
in the age group 30 to 44 
years. 
Harding, K. E., et 
al. (2012).  102 0 Age 
Correlation 
analysis 
There was no evidence for 
increased levels of anxiety in 
the younger onset MS group 
(Only abstract available) 
Ionescu, P., et al. 
(2012).  112 0 
Level of disability; 
Depression; Daily 
functioning; Quality 
of life;  
Pearson and 
Kendall 
methods.  
Level of disability, depression, 
daily functioning and quality of 
life were all strongly correlated 
with anxiety (p = 0.0001) (Only 
abstract available). 
Iriarte, J., et al. 
(2000). 155 0 Fatigue 
Kruskal 
Wallis H test 
Anxiety was associated with 
fatigue (Kruskal H=7.59, 
P<0.005). 
 
Janssens, A., et 
al. (2003). 101 101 
Prevalence of 
anxiety  ANOVA 
Prevalence =34% (eight 
months after diagnosis) 
Janssens, A., et 
al. (2004).  101 0 
Prevalence; Level 
of disability; Risk 
perception 
Multiple 
Regression 
Analysis 
Prevalence =34%. Higher level 
of disability reported by PwMS 
was a significant predictor for 
anxiety symptoms (b= 0.24, p 
=.002). Perceived 2-year risk 
was also a significant predictor 
for anxiety (b=0.78, p<0.001).  
 
Jones, K. H., et al. 
(2012) 4178 0 
Prevalence of 
anxiety; Age; Time 
since diagnosis; 
Depression; MS 
type 
Kruskal-
Wallis, 
ANOVA 
Prevalence =54%. There was 
a weak negative relationship 
between age and anxiety score 
(rho = 20.18, p <0.001) and 
between time since diagnosis 
and anxiety score (rho = 20.10, 
p<0.001). Depression and 
anxiety scores were positively 
correlated (rho = 0.565, 
p<0.001). Anxiety was most 
frequent among people with 
RRMS (56.5%). Anxiety scores 
were higher in women 
(p<0.001, N = 4287). There 
was no significant difference in 
anxiety scores between the 
genders for SPMS (not sig, N = 
396). Kruskall-Wallis tests 
showed that there was no 
significant difference in men’s 
anxiety scores for different 
types of MS (not sig, N = 
1226). However, women’s 
anxiety scores differed with 
type of MS (p = 0.017, N = 
2998), with the highest levels 
in RRMS. 
Jones, K. H., et al. 
(2013) 4500 0 Prevalence  
Descriptive 
Analysis 
There was a high prevalence 
of anxiety in PwMS (Only 
abstract available) 
Jones, S. M. & 
Amtmann, D. 
(2014) 405 0 Healthcare worry 
Multiple 
Regression 
Analysis 
Total level of health care was 
found to be a significant 
predictor for anxiety (b=0.363, 
p<0.01, R
2
=0.184)  
Jones, K. H., et al. 
(2014) 
                          
4 516 0 
Level of disability; 
Gender; Durations; 
Age 
Multiple 
Regression 
analysis 
Level of disability (b= 0.398), 
male gender (b=20.076), 
PPMS (b=20.062), disease 
duration (b=20.080), and age 
(b=20.218) (all p<0.001) were 
all significant predictors of 
anxiety.  This indicates that 
level of disability is the major 
contributor to the increase in 
the anxiety score, and that the 
other factors actually reduce 
the effect, with age being the 
most important of these 
(R
2
=0.184; Durbin-Watson 
1.984; ANOVA F=161.508, 
df=5, p<0.001).  
Jopson, N. M. & 
Moss-Morris, R.  168 0 
Illness 
representations  
Hierarchical 
Multiple 
Illness identity (b=0.20. 
p<0.05), cyclical timeline 
(2003) Regression 
Analysis 
(b=0.23, p<0.05) and illness 
coherence (b=0.18, p<0.05) 
(all types of illness 
representations) were all 
significant predictors of anxiety 
(R
2 
=0.23).  
Julian, L. J. & 
Arnett, P. A.  
(2009) 77 0 
Cognitive 
functioning 
Multiple 
Regression 
Analysis 
Cognitive functioning in MS 
was a significant predictor for 
anxiety in the regression model 
F (1, 68)=4.53, p<0.05 (R
2 
=0.35).  
Karadayi, H., et al. 
(2014) 31 31 
Disability; Fatigue; 
Depression; 
Cognitive 
Impairment Correlations 
Anxiety was significantly 
correlated with level of 
disability (r=0.69, p<0.01), 
depression (r=0.43, p<0.01) 
and fatigue (r=0.49, p<0.01). 
Anxiety was not correlated with 
cognitive impairment.  
Kehler, M. D. & 
Hadjistavropoulos, 
H. D. (2009) 246 0 
Health anxiety and 
coping 
Logistic and 
Hierarchical 
Regression 
Prevalence =28%. Anxiety did 
not significantly differ among 
individuals with different types 
of MS (F (2, 210) = 1.10, ns). 
Emotional Preoccupation 
coping was found to be a 
significant predictor for anxiety 
(R
2
=0.40, F(1,227)=152.90, 
p<.001). Participants with high 
health anxiety were 1.38 times 
more likely to have high 
generalized anxiety. Health 
anxiety and generalized 
anxiety demonstrated a strong 
positive correlation (r (231) = 
0.67, p < 0.001). 
Kikuchi, H., et al. 
(2013) 163 0 Employment 
Structural 
Equation 
Modeling 
Changes in employment status 
after MS onset were negatively 
associated with anxiety (b=-
0.25, p<0.05) 
Korostil, M. & 
Feinstein, A. 
(2007) 140 0 
Prevalence, 
Gender, 
Depression, 
Drinking; Social 
stress; Suicide 
T-tests and 
Discriminative 
Function 
Analysis 
Lifetime prevalence of any 
anxiety disorder= 35.7%. Prev. 
panic disorder = 10%, OCD= 
8.6%, and GAD=18.6%. 
Subjects with an anxiety 
disorder were more likely to be 
female (t (1) =7.7, p=0.06), 
have a history of depression (t 
(1)=22.0, p=0.001), drink to 
excess (t (1)=4.7, p=0.03), 
report higher social stress (t 
(1)= 3.6, p=0.001) and have 
contemplated suicide (t 
(138)=3.6, p=0.04). 
Kostaras, P., et al. 
(2008) 60 0 Cognitive deficits Correlations 
No correlation was established 
between anxiety and cognitive 
dysfunction (Only abstract 
available) 
Kraft, G. H., et al. 
(2012) 1,543 0 Prevalence 
Descriptive 
Statistics 
There was a higher prevalence 
of anxiety in PwMS in 
comparison to healthy controls 
(p<0.001) (Only abstract 
available) 
Krokavcova, M., 
et al. (2010) 184 0 Employment 
Stepwise 
Logistic 
Regression 
Patients without anxiety were 
2.64 times more likely to be 
employed. Not suffering from 
anxiety was a significant 
predictor of employment status 
(b=0.972, 95%CI: 1.23-5.67, 
p=0.012). 
Labuz-Roszak, B., 
et al. (2007) 122 0 
Prevalence; 
Fatigue 
Correlation 
Analysis 
Prevalence =26.2%. An 
association was found 
between anxiety and fatigue 
(Only abstract available) 
Leonavicius, R. & 
Adomaitiene, V. 
(2013) 312 0 
Prevalence; 
Gender; Age, 
Duration, 
Depression; level 
of social activity. 
Logistic 
Regression 
Prevalence =20.2%. Anxiety 
was found to be higher among 
females (22.4%vs 16.4%). 
Younger age (b=2.357, 
p<0.05), shorter MS duration 
(b=11.904, p<0.05), 
depression (b=17.283, p<0.05) 
and few MS group activities 
(b=8.222, p<0.005) were 
significant predictors of 
anxiety. Being socially active 
was not a significant predictor 
of anxiety among PwMS.  
 
Leonavicius, R. & 
Adomaitiene, V.  
(2011) 270 0 
Prevalence; 
Duration 
Depression Odds Ratios 
Prevalence =17%. Patients 
with shorter MS duration (<10 
years) had 2.52 times higher 
odds ratio to be diagnosed with 
anxiety. Patients with 
depression had 3.03 times 
higher odds ratio to be 
diagnosed with anxiety (Only 
abstract available).  
Leonavicius, R. & 
Adomaitiene, V. 
(2014) 137 0 
Prevalence; Sleep 
disturbances 
Multivariate 
Linear 
Regression 
Prevalence =19.7%. Sleep 
disturbances were found to be 
a significant predictor anxiety 
(b=3.362, CI 95% (1.113, 
5.885) 
Lester, K., et al. 
(2007) 82 0 
Level of disability; 
Cognitive 
impairment;  
 
Hierarchical 
Regression 
Analysis 
Level of disability (b=0.46) and 
cognitive impairment (b=0.46) 
were both significant predictors 
of anxiety (p<0.005, R
2 
=0.39) 
Levinthal, D. J. & 
Bielefeldt, K. 
(2014) 71 0 
Dyspeptic 
symptoms  
F-tests, 
Fisher Exact 
Tests 
PwMS patients with moderate 
to severe dyspepsia had 
higher anxiety compared to 
controls (62.5%vs. 27.3%) 
(Only abstract available) 
Liu, X. J., et al. 
(2009) 41 0 
Negative life 
events; Personality 
Correlation 
analysis 
There were higher levels of 
anxiety in PwMS than controls 
(p<0.001). Significant 
correlations were found 
between anxiety and negative 
life events (r=0.258), problems 
of family life (r=0.254) (both 
p<0.01), social functioning  
(r=0.247, p<0.05), extroversion 
(r=--0.296) and neuroticism 
(r=0.380) (both p<0.001). 
Lopes, J., et al. 
(2012) 119 0 
Prevalence; 
Fatigue 
Correlation 
analysis 
Prevalence =44.5%. Fatigue 
was associated with anxiety 
(OR 8.33, 95%CI 2.33-29.75, p 
< 0.001) (Only abstract 
available) 
Maia, D., et al. 
(2011) 25 0 
Neuropsychological 
functioning 
Correlation 
analysis 
There was no significant 
relationship between 
neuropsychological functioning 
and anxiety (Only abstract 
available) 
Marrie, R. A., et 
al. (2013) 4192 20,940 
Prevalence of 
anxiety  
Descriptive 
Analysis 
Prevalence =35.6% 
Medin, K. L., et al. 
(2014) 13 0 Epilepsy  
Correlation 
analysis 
Of those diagnosed with MS 
and epilepsy, 77% had 
clinically significant levels of 
anxiety (Only abstract 
available) 
Middleton, L. S., 
et al. (2006) 221 0 
Perception global 
functioning 
Multiple 
Regression 
Analysis 
Anxiety was found to 
significantly predict 
perceptions of global cognitive 
functioning (b = .55; t = 8.16; p 
< .001) but not objective 
cognitive performance. 
Milanlioglu, A., et 
al. (2013) 50 30 Coping strategies 
Correlation 
analysis 
There was a positive 
correlation with substance use 
and non-functional coping 
strategies for anxiety (no 
strength specified in paper). 
Milinis, K., et al. 
(2014) 260 0 Spasticity 
Correlation 
analysis 
There was a weak correlation 
between anxiety and spasticity 
(r=0.23,p< 0.05). (Only 
abstract available) 
Miljatovic, A. M. 
(2013) 98 0 Level of disability 
Correlation 
analysis 
A strong correlation was found 
between anxiety and level of 
disability (p= 0.0001). (Only 
abstract available) 
Mills, R. J. & 
Young, C. A. 
(2011) 635 0 Fatigue 
Linear 
regression 
High levels of anxiety were 
associated with greater fatigue 
(rho=0.426, mean difference 
1.30 logits, 95% CI 0.99–1.61, 
p < 0.001, R
2 
<0.3).  
Montel, S. R. & 
Bungener, C.  
(2007) 135 0 
Coping; Pain; 
Distress; Sleep ANOVA 
Prevalence anxiety= 4%. 
Anxiety had a significant effect 
on emotional coping strategies 
(WCC: p =0.005; CHIP: 
P<0.001). In the AVOVA, 
anxiety was negatively related 
to pain (-0.44), emotional well-
being (-0.52), distress (-0.39), 
cognitive functions (-0.42), 
general well-being (-0.35), and 
sleep (-0.31). WCC=Ways of 
Coping Checklist. 
CHIP=Coping with Health 
Injuries and Problems. 
Morrow, S. A., et 
al. (2014) 96 0 Prevalence 
Descriptive 
statistics 
Prevalence =24% (Only 
abstract available) 
Nicholl, C. R., et 
al. (2001) 96 0 
Prevalence; 
Disability 
Correlation 
analysis 
Prevalence =31%. There was 
a correlation between level of 
disability and anxiety (r=0.49, 
p<0.01) 
Niino, M., et al. 
(2012) 163 0 
Employment; 
Knowledge; 
Disability 
Structural 
Equation 
Modeling 
Level of disability was not 
associated with anxiety. 
Changes in employment status 
after onset of MS increased 
anxiety. Knowledge of disease 
information improved level of 
anxiety (Only abstract 
available). 
Noy, S., et al. 
(1995) 20 0 
Exacerbations; 
Duration Correlations 
Anxiety level was positively 
correlated with number of 
exacerbations (r=0.39 p=0.08) 
but not with disease duration. 
Ostacoli, L., et al. 
(2013) 232 0 PTSD 
Multiple 
Linear 
Regression 
Prevalence =5.17 % for PTSD. 
Levels of education 
(0R=0.672, 95% p=0.019) 
anxiety (0R=1.474, p=0.016) 
and depression (0R=1.398, 
95% p=0.022) were significant 
determinants of the presence 
of PTSD.  
Paredes, S. & 
Kirchner Nebot, T.  
(2012) 90 0 
Gender; Time since 
diagnosis 
Correlation 
analysis 
High levels of anxiety were 
present in both genders. There 
was no relationship between 
anxiety and time since 
diagnosis (Only abstract 
available).  
Pfaff, L., et al. 
(2014) 16 16 Level of disability  n/s (bivariate) 
Level of disability was 
associated with anxiety 
(p=0.03) (Only abstract 
available) 
Pieper, L., et al. 
(2012) 50 0 
Prevalence; 
Disability n/s (bivariate) 
Lifetime prevalence of any 
anxiety disorder =53.2% 
Anxiety was not associated 
with level of disability (Only 
abstract available).  
Poder, K., et al. 
(2009) 245 0 Social Anxiety 
Correlation 
analysis 
Prevalence of social anxiety= 
30.6% (SPIN). There was a 
strong correlation between 
social anxiety and generalized 
anxiety (r=0.59, p<0.01) and 
social anxiety and depression 
(r=0.56, p<0.01). Severity of 
social anxiety symptoms was 
correlated with reduced health-
related quality of life (r=-0.40, 
p<0.01) and not related to 
neurological disability 
Poder, K., et al. 
(2007) 265 0 Social Anxiety 
Multivariate 
Models 
Prevalence of social 
anxiety=29.8% (SPIN) and 
22.4% (MINI SPIN). Gender, 
age, EDSS and use of disease 
modifying drugs did not differ 
between groups with and 
without social anxiety. Those 
with social anxiety had lower 
health related quality of life 
scores (p<0.001) (Only 
abstract available).  
Reade, J. W., et 
al. (2012) 145 0 
Stress; Social 
support ANOVA 
Anxiety levels were 
significantly associated with 
high level of stress and lower 
levels of social support (F (3, 
125)=14.23, p<0.001). 
Roy Bellina, S., et 
al. (2010) 32 0 
Number of 
symptoms  
Correlation 
analysis 
A positive correlation was 
found between "the number of 
symptoms inherent to the 
disease" and anxiety (r=0.59, 
p=0.0004) (Only abstract 
available) 
Roy-Bellina, S., et 
al. (2009) 45 0 Coping strategies 
Correlation 
analysis 
Problem-focused coping was 
negatively correlated with 
anxiety (state: r=-0.410, 
p=0.0048; feature: r=-0.458, 
p=0.0013). Emotion-focused 
coping was positively 
correlated with anxiety 
(feature: r=0.554, p=0.0001) 
(Only abstract available).  
Sarisoy, G., et al. 
(2013) 76 76 
Prevalence; 
Disability 
Correlation 
analysis 
There was a high prevalence 
of anxiety in PwMS compared 
to the healthy controls.  Level 
of disability and high level of 
anxiety were correlated 
(r=0.355, p=0.002).  
Schwartz, C. E., 
et al. (1996) 139 0 Fatigue 
Multiple 
Regression 
Analysis 
Anxiety was not a predictor for 
fatigue in the regression 
model.  
Shabani, A., et al. 
(2007) 85 0 Prevalence 
Chi Square 
tests 
Prevalence of all anxiety 
disorders=22.4%. Prevalence 
of OCD was significantly 
higher compared to controls 
(p<0.05). Prevalence of GAD= 
11.8%, panic disorder = 1.2%, 
specific phobias=7.1% and 
OCD=11.8%. There was a 
significant association between 
anxiety and university 
education (p<0.05, df = 1, F
2 
= 
13.99). 
Sidorenko, T., et 
al. (2010) 148 0 
Prevalence; 
Adherence 
n/s (bivariate 
analysis) 
PwMS had higher levels of 
anxiety than controls  (38,5% 
Vs. 19,5% respectively; 
p<0.05).  Low adherence was 
associated with high anxiety 
(Only abstract available).  
Silva, A., et al. 
(2009) 231 0 Course of illness  
n/s (bivariate 
analysis) 
Level of anxiety was 
significantly higher in patients 
than controls (p<0.001). No 
significant differences for 
anxiety were found during 
course of illness (Only abstract 
available).  
Silva, A. M., et al. 
(2011) 159 0 Quality of life ANCOVA 
QoL was predicted by anxiety 
(Benign MS: F=4.39, p=0.045; 
Non-Benign MS: F=12.704, 
p=0.001) (Only abstract 
available).  
Simpson, R. J., et 
al. (2014) 3826 1,268,859 
Prevalence of 
anxiety  Odds ratios 
Anxiety was the 2
nd
 highest 
comorbid mental health 
condition for PwMS (OR=3.18). 
Smith, S. J. & 
Young, C. A. 
(2000) 88 0 
Prevalence; 
Depression; 
Perception of 
disability 
Descriptive 
statistics 
Prevalence =34%. Depression 
was associated with anxiety in 
two-thirds of depressed 
patients. There was no 
association between anxiety 
and perception of disability. 
Spain, L. A., et al. 
(2007) 580 0 
Prevalence; Quality 
of life 
Regression 
Analysis 
Prevalence =34%. Anxiety was 
found to be a significant 
predictor for quality of life as 
indicated under the following 
QoL sub-scales: anxiety 
predicted physical functioning 
(b=.0.19, p<0.05), bodily pain 
(b=-0.19,p<0.01), general 
health (b=-0.13, p<0.05), 
vitality (b=-0.12, p<0.05), 
social function (b=-0.12, 
p<0.05), emotional functioning 
(b=-0.42, p<0.01) and mental 
health (b=0.5, p<0.001). 
Stenager, E., et 
al. (1994) 94 0 
Cognitive 
Dysfunction; 
Course of illness 
Correlation 
analysis 
Level of disability was 
correlated with anxiety (F-
Test=2.61, p < 0.05; df. 1.92). 
Trail Making (cognitive 
functioning) was also 
correlated with anxiety (no 
strength specified). No 
significant correlation was 
found between the course of 
illness and State anxiety (F= 
1.73; p=0.18, d.f. 1.92) and 
Trait anxiety (F=0.18; p=0.84, 
df. 1.92).  
Suh, Y., et al. 
(2010) 96 0 
Prevalence; 
Physical Activity  
Correlation 
analysis 
Prevalence =41%. Physical 
activity was not correlated with 
anxiety (r = -0.021; p>0.05). 
Szilasiova, J., et 
al. (2011) 114 0 
Prevalence; Quality 
of LIfe 
Multiple 
Linear 
Regression 
Prevalence =27%. Anxiety was 
found to be a significant 
predictor of QoL (b=–0.51, p < 
0.001, R
2 
=0.613)  
Tadic, D. & Dajic, 
V. (2013) 50 0 Quality of life 
Correlation 
Analysis 
A strong correlation was found 
between high anxiety and 
overall QoL (r=-0.674, p< 
0.001)  
Tan-Kristanto et al 
(2015) 129 0 
Resilience, self-
efficacy, coping 
styles; depression 
Pearson’s 
correlation; 
hierarchical 
regres- sion 
Denial (b=0.29, p < 0.001), 
level of disability  (b=0.23, p < 
0.05) and lower levels of 
personal competence (b=-
0.26, p < 0.05) were 
analyses independent significant 
predictors of the anxiety score 
(R
2 
= 0.364)  
Theaudin et al 
(2016) 711 0 
Depression; 
Gender 
Linear 
regression 
analysis. 
 
Higher HADS anxiety scores in 
females (t = −4.555, p < 
0.001),52.1% of females and 
37.8% of males were deemed 
clinically anxious (HADS 
anxiety ⩾ 8; χ2 = 12.532, p < 
0.001). A gender com- parison 
of depression together with 
anxiety revealed higher 
frequencies of both these 
symptoms in women than in 
men (32.3% of females 
depressed and anxious vs. 
23.4% of males, χ
2 
= 5.795, p 
= 0.02).  
Thornton, E. W., 
et al. (2006) 39 40 Self-efficacy; Worry 
Correlation 
analysis 
Anxiety was significantly 
correlated with self-efficacy 
and worry(r=0.59-WQMS) 
(r=0.77-PSWQ)(both p<0.01).  
Tsivgoulis, G., et 
al. (2007) 86 0 
Level of disability; 
Level of education 
Multiple 
Linear 
Regression 
Analyses 
 
Level of disability (b=+0.430, p 
< 0.001) and level of education 
(b =-0.235, P < 0.041) were 
significant predictors for 
anxiety.  These accounted for 
18.5% (R
2 =
 0.185) and 5.5% 
(R
2 
= 0.055) of the variance in 
anxiety. Initial association 
between education and anxiety 
failed to retain statistical 
significance in the multiple 
linear regression analyses 
performed both with the 
backward and forward 
procedure (unstandardized 
linear regression coefficient: -
0.471; 95% CI -1.170 to 0.228; 
b= -0.143; p= 0.184).  
Uca et al (2016) 55 56 
Prevalence; 
Personality 
disorders; 
Depression 
t test; Mann- 
Whitney U 
test c
2
test/ 
Fisher’s exact 
test  
38% had an anxiety disorder. 
MS patients with any 
personality disorder had 
significantly higher frequency 
of GAD (p=0.008), any anxiety 
disorder (p=0.005), and post-
traumatic stress disorder 
(p=0.037),  
Uguz, F., et al. 
(2008) 74 0 
Anxiety subtypes; 
Exacerbation; 
Disease duration  
Logistic 
Regression 
Analysis  
Prevalence rate for GAD= 
18.9%, specific phobia=18.9% 
and OCD=14.9%. The 
predictors of any anxiety 
disorder were presence of the 
exacerbation phase of MS (B 
=-1.233, Wald x
2 
=5.603, df 1, 
p=0.018) and shorter disease 
duration (B=-0.137, Wald 
x
2
=4.376, df 1, p=0.036).  
Van Der Hiele, K., 
et al. (2014) 44 0 Employment 
Correlation 
analysis 
There was no correlation 
between employment and 
anxiety symptoms. 
Van Der Hiele, K., 
et al. (2010)  128 0 
Subjective 
cognitive 
functioning 
Correlation 
analysis 
Participants with subjective 
executive problems had higher 
anxiety scores (p< 0.001) than 
participants without subjective 
executive problems. Objective 
executive performance was not 
correlated with anxiety (Only 
abstract available).  
Van der Hiele, K., 
et al. (2012) 715 0 
Psychosocial 
stress 
Logistic 
Regression 
Higher psychosocial stress 
was found to be a significant 
predictor of higher anxiety 
scores (b=0.21, CI 95% (1.16, 
1.31) p<0.001) R
2
=0.22 (Cox 
and Snell), 0.30 (Nagelkerke); 
model χ
2
(6)=151.3.  
Van der Hiele, K., 
et al. (2012) 114 0 
Executive cognitive 
performance ANOVA 
Patients with MS 
underestimating their executive 
cognitive performance had 
higher levels of anxiety 
(F2,105 = 7.4, p = 0.001).  
Visser, L. H., et al. 
(2009) 708 0 
Cognitive 
complaints 
Correlation 
analysis 
PwMS with cognitive 
complaints had higher levels of 
anxiety compared to PwMS 
without cognitive complaints 
(p< 0.001) (Only abstract 
available).  
Voiticovschi-
Iosob, C. & 
Moldovanu, I. 
(2013) 54 0 Pain 
Descriptive 
Statistics 
Anxiety was associated with 
chronic pain in 87.8 % of 
PwMS (Only abstract 
available).  
Vuger-Kovacic, 
D., et al. (2007) 457 0 Duration 
Correlation 
analysis 
Anxiety did not significantly 
increase with longer duration 
of MS. 
Weisbrot, D., et al. 
(2012) 45 0 Prevalence 
Descriptive 
Analysis 
Prevalence. =44.4% (Only 
abstract available). 
White, C. P., et al. 
(2008)  145 0 
Speech difficulties; 
Pain; Fatigue; 
Depression; Health 
distress 
Correlation 
and 
Regression 
Analyses  
Anxiety was correlated with 
speech difficulties (r=.32, 
p<0.001), pain (r=.34, 
p<0.001), fatigue (p=.30, 
p<0.001) and 
depression(r=.74, p<0.001). It 
was not predictive of health 
distress in the regression 
model with other factors. 
Ziegler, K., et al. 
(2010) 50 0 PTSD ANOVAS.  
12% of the PwMS had a PTSD 
lifetime diagnosis lifetime and 
24% had a PTSD associated 
with MS-diagnosis. MS-
patients with PTSD showed 
statistically significant lower 
self-efficacy, sense of 
coherence and social support 
(Only abstract available).  
Zorzon, M., et al. 
(2001) 97 110 
Biological 
correlates 
Correlation 
analysis 
The anxiety did not correlate 
significantly with any of the 
measures of regional and total 
lesion loads and brain volume. 
 
Results and Strengths of Associations for Prospective 
Studies 
 
Authors, Year 
No. 
Patients 
No. 
Controls 
Factor/s 
investigated 
Type 
analysis Results 
Bianchi, V., et 
al. (2014) 39 39 
Prevalence and 
Coping 
Multivariable 
linear 
regression 
analyses  
Prevalence =53.8%.  There were higher 
scores for anxiety (p < 0.001) in patients 
compared with controls. ‘Accepting 
responsibility’ coping (b = 0.53; p < 
0.001) and ‘Seeking social support’ 
coping (b = 0.22; p = 0.02) were both 
predictors of anxiety (R
2
=0.29). Over the 
24-month follow-up, there was a 
significant reduction in anxiety (p < 
0.001). At the end of follow-up, changes 
in depression and anxiety scores were 
strongly correlated with eachother 
(r=0.70, p<0.001). This decrease was 
also correlated with a decrease in 
‘Accepting responsibilities’ coping scores 
for anxiety (r = 0.43; p = 0.018).   
Brown, R. F., 
et al. (2009) 101 0 
Depression, 
Immunotherapy; 
Coping; 
Optimism 
Regression 
models 
Depression (b=1.07, p<0.0001) and 
baseline immunotherapy status (b=-4.85, 
p<0.0001) best predicted later anxiety 
levels, followed by smoking (b=2.5, 
p<0.003), no relaxation training (b=-2.56, 
p<0.0011), and low dispositional 
optimism (b=-0.35, p<0.0017). 
Burns, M. N., 
et al. (2013) 121 0 Exacerbations 
Logistic 
regression  
Pseudo-exacerbations were associated 
anxiety symptoms, t (1072) = 3.19, p = 
.001. There was a significant main effect 
of confirmed exacerbations on anxiety 
symptoms  (t (1072) = 2.93, p = .004). 
Baseline anxiety symptoms were not 
significantly associated with risk for 
pseudo- or confirmed exacerbations (ps 
> .14). Increases in anxiety symptoms 
relative to baseline predicted subsequent 
onset of new pseudo-exacerbations (Z = 
2.30, p = .02). 
Christodoulou, 
C., et al. 
(2009) 38 38 
Cognitive 
change; 
Cognitive 
Performance 
Multiple 
Regression 
and 
Pearson 
Correlations 
Anxiety as a significant predictor of 
cognitive change (b = -0.569, p <0.01, 
R
2
=0.458). A correlation was also found 
for anxiety and cognitive performance 
(r=-0.523, p<0.01).  
Dalos, N. P., 
et al. (1983) 73 
23 
(Spinal 
Chord 
patients) Relapse T-tests 
There were significant levels of anxiety in 
PwMS experiencing relapse (p<0.001) 
compared to controls (no strength of 
association specified) 
Diaz-
Olavarrieta, 
C., et al. 
(1999) 44 25 
Prevalence; 
Frontotemporal 
changes 
The 
Kruskal-
Wallis test  
Prevalence =37%. Anxiety had no 
significant association with 
frontotemporal changes measured by the 
MRI. No associations were found 
between anxiety and level of disability, 
gender or age.  
Giordano, A., 
et al. (2011) 197 0 
Gender; 
Depression; 
Duration 
Multivariate 
Linear 
mixed 
model 
analysis 
There was a statistically significant 
decrease in anxiety score at the six-
month follow-up. Multivariate linear 
mixed model analysis showed that the 
decrease of anxiety scores over time 
remained significant (F=4.96, DF(2, 97), 
p = 0.008) after controlling for clinical 
variables (disability, depression, 
duration) and demographic variables 
(sex, age, education). Of these, female 
sex (F=15.80, DF (1, 114), p<0.001) and 
depression (F=24.80, DF (1, 23), 
p<0.001) each had an independent 
influence on anxiety.  
Hartoonian et 
al (2015) 513 0 
Depression; 
Time since 
onset of MS; 
EDSS; pain; 
fatigue 
Hierarchical 
regression 
model 
Anxiety (β <.001), employment (β =.07) 
and non-somatic depressive symptoms 
(β =.10) at baseline significantly 
predicted anxiety at time 2, ps<.05 
Hoang et al ( 
2016) 5084 24771 
Depression; 
antidepressant 
and anxiolytic 
Logistic 
regression 
analyses 
In the pre-diagnostic period, the OR for 
having a diagnosis of depression and 
anxiety is 1.4 (95% confidence interval 
(CI) =1.05–1.88). In the post-diagnostic 
period the OR is 1.23 (CI= 0.92–1.64) for 
prescriptions, 
 
 depression and anxiety diagnosis.  
Janssens, A., 
et al. (2006) 101 76 
Disability; Time 
since diagnosis 
SAS Proc 
Mixed  
 Prevalence =34% at baseline, 30% at 
follow-up. Mean anxiety scores of 
patients remained higher than controls at 
all times (all p < 0.05). Higher level of 
disability was associated with higher 
levels of anxiety in patients (all P 
<0.001). Time since diagnosis was not 
associated with levels of anxiety. No 
association found between anxiety and 
changes in disability status. Anxiety at 
baseline correctly identified 55% of the 
participants with high anxiety at follow-up 
(sensitivity =55%), and 85% of those who 
will not develop high levels of anxiety 
during follow-up. 
Johnson, K., 
et al. (2012) 613 0 Social support T-tests 
The high social support group had a 
reduction in anxiety scores in contrast to 
the population norm (p < 0.001) (Only 
abstract available).  
McCabe, M. 
P. (2005) 243 184 Gender, Coping 
MANOVA 
and 
Regression 
No significant sex or sex-group 
interaction demonstrated significant 
differences between the groups in levels 
of anxiety ((F (2,421)=8.92, P<0.001). 
With all of the variables in the regression 
equation, anxiety at Time 1 was the only 
unique predictor for anxiety 18 months 
later (F (1,95)=45.47, P<0.001, R
2
=.32). 
In the non-exacerbation group, coping 
variables did not explain variance of 
anxiety. With all of the variables in the 
regression equation, anxiety at Time 1 
was the only unique predictor for anxiety 
18 months later (F(1,149)=73.44, 
P<0.001, R
2
=.33).  
McKay et al 
(2016) 949 0 
Depression; 
Smoking; 
Alcohol 
Dependence; 
Disability 
Pearson χ
2 
test/ 
Fisher’s 
exact test, 
logistic 
regression. 
 
Alcohol dependence was associated with 
increased odds of anxiety (OR: 1.88; 
95% CI: 1.37–2.57). The association 
persisted after adjusting for age, sex, 
EDSS, and smoking status (OR: 1.84; 
95% CI: 1.32–2.58) Smoking was 
associated with increased odds of 
anxiety (unadjusted OR: 1.32; 95% CI: 
1.05–1.65). When adjusted for age, sex, 
EDSS, and alcohol dependence, the 
relationship persisted (OR: 1.29; 95% CI: 
1.02–1.63). 
 
 
Olivares, T., 
et al. (2012) 50 0 
Cognitive and 
Clinical 
variables 
Pearson 
Correlations 
At baseline there was a correlation 
between neuropsychological functioning, 
(r=0.442, p<.05), QoL (r= -.627, p<.001) 
and years since onset (r= -.611, p<.001) 
with anxiety. Anxiety symptoms were 
markedly related with low disease 
duration. Follow-up measures found 
fatigue (r=.472, p<.001), QoL mental (r= -
.727, p<.001) and QoL physical (r= -.518, 
p<.001) were correlated with anxiety. 
Years since onset and 
neuropsychological performance were 
not correlated with anxiety at follow-up 
(Only abstract available).  
Pakenham, K. 
I. & Samios, 69 69 Coping 
Multilevel 
Modeling 
Anxiety significantly associated with low 
acceptance (-0.41) and mindfulness 
C. (2013) (0.40) and high depression (0.68) (all 
p<0.001).  
Pekmezovic, 
T., et al. 
(2012) 109 0 Quality of life T-tests 
Baseline scores for quality of life were 
associated with anxiety (Only abstract 
available).  
Potagas, C., 
et al. (2008)  37 0 
Stressful life 
events; Relapse 
Linear 
Mixed 
Model 
Zero stressful events are associated with 
a mean anxiety score of 11.7 (95% CI 
[10.2–13.1]), one event with an anxiety 
score of 14.1 (95% CI [12.7–15.4]), two 
events with an anxiety score of 16.1 
(95% CI [14.5–17.8]), three with a 
anxiety score of 20.3 (95% CI [18.7–
21.9]), and four or five events with an 
anxiety score of 22.2 (95% CI: [20.2–
24.1]). In the univariate analysis the risk 
of a relapse was associated with high 
level of anxiety  (2.9, 95% CI: (1.3-6.4) 
P=0.008). 
Solari, A., et 
al. (2010) 121 0 
Prevalence; 
Depression; 
Gender 
Multivariate 
linear 
regression 
Prevalence = 43%. Female gender (p = 
0.02) and depression (p < 0.001) were 
predictors of anxiety (R
2
= 0.54; p< 
0.001). Anxiety decreased (p < 0.001) 
between 1 and 6-months (no influence of 
the intervention). (Only abstract 
available) 
Wood, B., et 
al. (2013) 198 0 
Age; Duration of 
illness; Level of 
disability; 
Depression; 
Fatigue 
Regression 
analysis 
At cohort entry, prevalence = 25.4% 
Older age at cohort entry was associated 
with lower prevalence of anxiety 
(RR=0.88). Disease duration at cohort 
entry was not associated with risk of 
prevalent anxiety (p=0.33). A higher 
disability score was not associated with 
anxiety (0.75). Anxiety and depression 
(r=0.51) and anxiety and fatigue (r=0.25), 
were correlated. Prevalence of anxiety 
decreased by 8.1% per year of cohort 
observation (RR=0.92 (95%CI 0.86–
0.98), p=0.009). However this effect was 
driven by a strong decrease of 14.6% per 
year among females (RR 0.85 (95%CI 
0.79–0.93), p<0.001), with no significant 
change over time in males (RR 1.03 
(95%CI 0.90–1.17), p=0.77).  
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Highlights 
 Despite the literature indicating the high prevalence of anxiety amongst 
PwMS no systematic review has been conducted to date. 
 One hundred and thirty one studies and abstracts were included in this 
review in order to give a comprehensive overview of the physical, 
cognitive, social and psychological factors associated with anxiety 
amongst PwMS.  
 Due to the high levels of comorbidity with depression, many PwMS are 
likely to benefit from psychological and pharmacological interventions 
targeting both anxiety and depression. 
 
 
